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ABSTRACT
Molecular dynamics (MD) simulation has been widely used in understanding the physical
basis of the structure and function of biological macromolecules. However, its
application in pharmaceutical research is still at an early stage. This dissertation attempts
to establish the use of MD simulation in studying several important pharmaceutical mass
transfer processes. The three-series study included (1) the understanding of drug crystal
dissolution at molecular level, (2) the elucidation of an unique mechanism for facile
polymorphic transformation of crystalline drugs in solutions, and (3) the determination of
drug–polymer interactions at water–crystal interface and the implications to
crystallization inhibition.
A drug crystal dissolution into aqueous solution was simulated successfully for
the first time on acetaminophen crystal Form I. The results revealed distinct corner &
edge effect and differentiated dissolution rate among the three crystal surfaces of (001),
(101) and (100), which correlated strongly with total interaction energies among the drug
molecules and between the drug and water molecules. This study helped us gain
additional fundamental understanding in the relationship between dissolution rate and
particle size and morphology.
A series of MD simulations and experimental methods were utilized to evaluate
the thermodynamic and kinetic forces that control the polymorphic transformation in
solutions. Acetaminophen Form II, a metastable crystalline form which readily converts

xix

to the themodymically stable Form I when in contact with solution was studied. It was
found that the facile polymorphic transformation is not attributed to the solubility
differences; rather it is caused by a unique mechanism of surface facilitated phase
transformation (SurFPT). This new mechanism is able to promote faster polymorphic
transformation than the well-known mechanism of solution-mediated phase
transformation (SMPT), thus it is more detrimental.
In the third study, the molecular mechanism of crystal surface specific drug–
polymer interaction was investigated by simulating tolazamide crystals in the presence of
hydrated PEG-b-PLA, a diblock copolymer. The results from the simulations
demonstrated the polymer’s strong interaction with the (001) face, weaker interaction
with the (010) face and minimal to no interaction with the (100) face, which matched
remarkably well with the reported crystal habit alteration by the preferential interaction of
PEG-b-PLA primarily with the (001) and partially with (010). Interestingly, van der
Waals interactions were identified as the dominant forces (accounts for 77–93% of total
interaction energies) that enabled such strong drug–polymer interactions. These findings
suggest that polymers capable of forming strong hydrophobic interactions are more
effective in inhibiting crystallization of poorly-water soluble and hydrophobic drugs in
aqueous media than those with hydrogen bonding capacities. Such in-depth analysis and
understanding facilitate the rational selection of polymers in designing supersaturationbased enabling formulations.

xx

CHAPTER ONE
BACKGROUND
This dissertation is concerned with three important pharmaceutical mass transfer
phenomena taking place in aqueous solutions: (1) the dissolution of drug crystals, (2) the
polymorphic transition, and (3) the inhibition of crystal growth through drug–polymer
interactions. These three topics will be briefly reviewed in this section. The main focus of
this dissertation is to apply new methodologies, especially molecular dynamics (MD)
simulation to gain a better mechanistic understanding of these phenomena. Thus, the
background of MD simulations will also be briefly reviewed in the context of drug
dissolution and drug–polymer interactions.
Drug Dissolution
Dissolution is defined as the process by which a solute forms a solution in a solvent. It is
a kinetic process quantified by rate and driven by equilibrium solubility. In the
dissolution of crystalline solids, the crystal structure of the solute disintegrates as separate
ions, atoms, or molecules. How the solute and solvent interact with one another
determines the thermodynamic energies involved, such as the heat and entropy of
dissolution. In order for dissolution to occur, the overall Gibbs free energy must be
negative. Dissolution will continue until the Gibbs free energy becomes zero at which the
equilibrium solubility is established.

1

2
Dissolution and Drug Development
The basic theories and laws of dissolution have been established in chemistry since
the late 19th century.1 In the pharmaceutical field, the dissolution process is of
fundamental importance to the design, development, manufacture and quality control of
drug products for the following reasons: (1) the large majority of active pharmaceutical
ingredients (API) and inactive ingredients (or excipients) are solids; (2) these solids often
undergo dissolution and precipitation processes during the manufacturing process of the
API’s and drug products and (3) most importantly, before the therapeutic effect of a drug
can be realized, the drug must go into solution at the site of absorption in order to cross
the biological membrane into the systemic circulation (Figure 1). Since the rate at which
a drug dissolves from a dosage form often affects its rate and/or extent of absorption (also
referred to as bioavailability), dissolution is considered one of the most critical steps in
oral drug absorption. This is particularly the case for sparingly soluble drugs.

Figure 1. Drug dissolution and absorption of orally administered solid tablet dosage forms in the gastrointestinal (GI) tract.

3

4
In general, the rate of drug dissolution is influenced by the physicochemical
properties of the drug substance, formulation and manufacturing process of the dosage
form. Over the past decades, extensive studies have been conducted to evaluate
thermodynamic and kinetic factors affecting dissolution of drug substances. The
thermodynamic factors relate to the intrinsic solid-state properties such as solubility
which changes with different solid forms (polymorphs and amorphous forms) and with
other conditions (dissolution media, temperature, pH, buffer type, and ionic strength).
The extrinsic factors that drive the kinetic process include particle surface area,
hydrodynamics (stirring rate), and fluid viscosity. Besides the solid form and surface area
which may change during dissolution, other aforementioned variables can be controlled
in dissolution testing. Polymorphism is very common among drug substances, and
different crystal forms have been shown to exhibit different dissolution and in vivo
performance in both animal models and human subjects.2,3 As a result, many approaches
have been investigated for enhancing the solubility and dissolution properties such as the
use of salts and amorphous solid dispersions. These formulation approaches are
collectively called enabling technologies. Enabling formulations have a tendency to
crystallize back to the parent form crystals after forming supersaturated solutions during
dissolution. Therefore, thorough characterization of the supersaturation maintenance and
understanding of the likely consequences of crystallization during dissolution are
recognized as an essential part of rational drug development.

5
Methods of Assessing Dissolution
of Pharmaceutical Solids
Models that are widely used to describe dissolution process are the Noyes-Whitney
equation4 and the Nernst-Brunner diffusion layer model,5 as shown schematically in
Figure 2.

Figure 2. Schematic illustration of diffusion layer dissolution model from a planar
surface.
Noyes-Whitney equation:

dQ
 k(C S  Cb )
dt

Nernst-Brunner equation:

dQ DA

(CS  Cb )
dt
h

Where dQ/dt = dissolution rate; k = dissolution rate constant; CS = solubility; Cb = bulk
solution concentration; D = diffusion coefficient of the solute; A = surface area; and h =
diffusion layer thickness. They were derived by applying Fick’s first law for mass flux
under the assumption of (1) presence of a stagnant layer between solid and the bulk
solution, (2) constant diffusion layer thickness under fixed hydrodynamics, (3) constant
concentration gradient (steady-state), and (4) diffusion-controlled transport.

For particulate dissolution, three diffusion-controlled models have been reported

6

6

for spherical particles. It is assumed that dissolution rate is proportional to surface area of
the sphere, as illustrated in Figure 3.

Figure 3. Concentration gradient from the diffusion layer to the bulk in dissolution of a
spherical particle,6 where h is the diffusion layer thickness, Cs is the equilibrium
solubility and Cb is the drug concentration in the bulk at any given time, and r is the
radius of the spherical particle.

7
One of the spherical dissolution models is the cube-root law by Hixson and
Crowell.6
Hixson and Crowell equation:
In the equation, W is the particle weight, W0 is the initial particle weight, t is time
and k is the dissolute rate constant. During the dissolution of spherical particles, the cubic
root of the total weight at a given time, t, is decreasing from the cubic root of the original
weight at a rate of kt. The rate constant, k, is expressed as

, where ρ is

particle density, N is number of particles, D is diffusion coefficient, Cs is equilibrium
solubility and h is diffusion layer thickness. The particles by the definition of the model
should be monosized. Particles with different particle size distributions and different
shapes are too complex to model.
Dissolution rate generally is expressed as the mass of solute appearing in the
dissolution medium per unit time (e.g., mass×sec–1), but dissolution flux is expressed as
the rate per unit area (e.g., mass×cm–2 sec–1). Depending on the study objectives, different
dissolution test methods are utilized for assessing the drug substance and factors affecting
dissolution.
Intrinsic Dissolution
The intrinsic dissolution rate (IDR) refers to the rate of mass transfer per area of
dissolving surface under sink conditions (Cb ≤ 0.1 × Cs). Essentially, it is the initial
dissolution rate long before the saturation solubility is reached. Since Cb << Cs, the

8
Nernst-Brunner equation can be simplified to

dQ DA
DA

(CS  Cb ) 
CS . This
dt
h
h

simplified equation means that the dissolution rate measured under sink conditions is
directly correlated to how fast the compound is released from the crystal lattice into
solution which is solely determined by intrinsic solid state properties of the drug.
According to the United States Pharmacopeia (USP), IDR is the dissolution rate of pure
substances under the condition of constant surface area. This allows different solid forms
to be compared in dissolution rate by holding the testing conditions constant (surface
area, dissolution medium, stirring rate, temperature, pH, ionic strength, etc.). Thus IDR is
considered a tool in the functionality and characterization of bulk drug substances.
Two types of apparatus are described in Pharmacopeias for the intrinsic dissolution
test: a stationary disk system, listed only in the USP, and a rotating disk system, known
as “Wood’s apparatus,” listed in the USP, the European pharmacopeias (EP) and the
British pharmacopeias (BP).7 These apparatus measure the release from a compact
consisting of pure API with a flat and well-defined surface area into a test medium
(Figure 4). A difference between the two procedures is the source of fluid flow over the
dissolving surface. In the rotating disk procedure, fluid flow is generated by the rotation
of the die, but for the stationary disk procedure, the fluid flow is generated by a paddle or
other stirring device.

9
(a)

(b)

Figure 4. IDR test system. Schematic diagram of (A) the rotating disk apparatus (Wood
Apparatus) and (B) the stationary disk apparatus (Source: USP37).

10
Powder Dissolution
Solid drug substances are, in most cases, harvested through crystallization or
precipitation in the manufacturing process. The resultant final APIs are composed of fine
particles with a wide range of shapes, sizes and surface properties. For spherical particles,
diffusion-controlled dissolution rate can be calculated once IDR of the drug is
determined.8,9 However, the real world drug particles are almost never spherical. It is
nearly impossible to accurately and reliably estimate the size, size distribution and
surface areas of particles having various irregular shapes. Hence, the dissolution rate of
powders needs to be measured experimentally.
To determine the dissolution rate of powders in an aqueous medium, USP
Apparatus 1 and Apparatus 2 shown in Figure 5 are usually used. They are also known as
basket and paddle dissolution methods, respectively, and are typically used for
dissolution testing of tablet and capsule dosage forms as well. The test procedures
involve introduction of small and known quantity of sample powders into an appropriate
dissolution medium, followed by analysis of solution concentration at predetermined time
intervals. The concentration–time curves (dissolution profiles) obtained from the powder
dissolution tests can be used for assessing how API variables may affect dissolution rate,
assuring consistent quality of the API, comparing drug substance of different solid state
properties, helping guide product and process development, and ultimately ensure
consistent drug absorption following administration of solid dosage forms.

11
(a)

(b)

Figure 5. Powder dissolution system. Schematic diagram of (A) USP Apparatus 1 where
the dosage form is placed inside the basket and the basket rotates during dissolution to
provide mixing, and (B) USP Apparatus 2 where the dosage form is place on the bottom
of the flask in a sinker and the paddle rotates to provide mixing (Source: Metrolab).
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Despite the well-established dissolution methods to control the product quality and
understand formulation performance, dissolution at the molecular level in large part has
not been adequately studied.
Polymorphism and Polymorphic Transition
Drug Property Change due to Polymorphism
The active pharmaceutical ingredient (API) is the drug portion in the
pharmaceutical dosage forms. Most APIs are crystalline solids due to the ease of
purification by crystallization processes and a better chemical stability in the solid state.
However, a crystalline solid may not be physically stable because it can rearrange into
different internal crystalline structures by varying molecular packing, conformation,
hydrogen bonding pattern, chirality and tautomerization. This physical instability gives
rise to polymorphism, the ability of a substance to exist as two or more crystalline phases
that have different arrangements and/or conformations of the molecules in the crystalline
lattice.10
Polymorphism induces a long list of solid state property changes.10,11 The different
molecular packing affords changes in molar volume and density, refractive index,
electrical and thermal conductivity, and hygroscopicity. The thermodynamic properties
are altered, resulting in differences in melting and sublimation temperatures, internal
energy, enthalpy, entropy, heat capacity, free energy and chemical potential,
thermodynamic activity, vapor pressure, and solubility. Spectroscopic properties are also
different, such as electronic (UV), vibrational (IR), rotational (far-IR or microwave),
nuclear interactions. The kinetic properties that are modified include dissolution rate and
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rates of solid state reactions. In the surface property arena, the changes are in surface free
energy, interfacial tensions, and crystal habit. Finally, mechanical properties are also
different including hardness, tensile strength, compatibility, tableting, powder handling,
flow, and blending.
These changes formed the basis for analytical methods to detect and analyze
polymorphism. The commonly used characterization techniques include optical
microscopy (based on reflective index change), thermal analysis such as differential
scanning calorimetry (DSC), based on the thermodynamic property, heat capacity and
melting point changes), single crystal or powder X-ray diffraction (PXRD, based on
different packing distance), Infrared and Raman spectroscopy (based on vibrational
property changes), solid-state nuclear magnetic resonance spectroscopy (SSNMR, based
the chemical shift anisotropy and the internuclear dipolar coupling), and so forth.
A lot of these changes have a profound impact to pharmaceutical formulation
development. For example, mechanical property changes lead to a difference in powder
flow, blending and tableting. Different reaction rates cause the chemical stability
differences among the polymorphic APIs. However, the most substantial impact is the
change in solubility and dissolution rate. When a solid form converts to the
thermodynamically more stable form, its solubility decreases, and so does its dissolution
rate, resulting in significantly altered pharmacokinetic factors such as rates of absorption
and drug bioavailability. This problem became significantly worse for poorly watersoluble drugs for which the solubility and dissolution rate are already undesirable. If the
thermodynamically stable form is not discovered during the earlier stages of development
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and a metastable form is used in the formulation, there is a risk that the metastable form
will recrystallize into the stable form during product manufacturing and storage resulting
in reduced product performance in vivo. For this reason, rigorous polymorph screening
and characterization to discover the most stable form and to understand the complex
polymorphism of each drug candidate have been implemented in the early stages of drug
development in every pharmaceutical company.
Polymorphic Transformation
Polymorphic transformation from the metastable polymorph to the stable
polymorph is dictated by thermodynamics. In a pair of polymorphs, Polymorph I and
Polymorph II, the stability relationship between the two polymorphs is determined
entirely by their free energy differences at different temperatures.12 The free energy of a
particular solid is expressed by the following equation:
 G   H  T S

where G is the Gibbs free energy, H is the enthalpy, T is temperature, and S is the
entropy. Thus, the free energy for the transition from Polymorph I to Polymorph II:

GI II  GII  GI  ( H II  TS II )  ( H I  TS I )  H I II  TS I II
where H III  H II  H I and S III  S II  S I . At any given temperature, three
possibilities exist:
1. GI II  0 : Polymorph II has lower free energy, is therefore more stable than
Polymorph I. The transition from Polymorph I to Polymorph II occurs spontaneously.
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2. GI II  0 : Polymorph I has lower free energy, therefore, the transition from
Polymorph II to Polymorph I is a spontaneous process.
3. GI II  0 : Polymorph I and Polymorph II has the same free energy. Therefore,
both polymorphs have equal stability. There will be no overall transition between the two
polymorphs.
The temperature at which GI II  0 is defined as the transition temperature (Tt). If
Tt is located below the melting points of both polymorphs, the two polymorphs are
enantiotropically related, the representative phase diagram of which is shown in Figure
6a. Therefore below Tt, Polymorph I is more stable. Above Tt, Polymorph II is more
stable.
If Tt is located above the melting points of both polymorphs, the two polymorphs
are monotropically related, the representative phase diagram of which is shown in Figure
6b. In this system, Polymorph I is more stable throughout the temperature range.
In either monotropic or enantiotropic systems, polymorphic transition can occur. In
the monotropic system (Figure 6b), Polymorph II has a higher free energy than
Polymorph I until it melts. Therefore, below the melting point, Polymorph II will sooner
or later convert to Polymorph I. The rate of conversion depends on the experimental
conditions. The enantiotropic system (Figure 6a) is a little more complicated. The free
energy relationship reverses when Tt is reached. Below Tt, Polymorph 2 will eventually
converts to Polymorph 1. However, above Tt, Polymorph 2 will never convert to
Polymorph 1. For polymorphic forms exhibiting an enantiotropic relationship,
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determination of the Tt, is essential to control polymorphism. For example, if the Tt is
55 °C and the temperature used in API manufacturing ranges from 45 to 65°C, then the
drug could crystallize out as Polymorph I in one batch and as Polymorph II in another. In
order to consistently manufacture Polymorph I, the crystallization temperature needs to
be maintained significantly below 55 °C.
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Figure 6. Thermodynamic phase diagrams of polymorphs. (a) Enantiotropy; (b)
Monotropy. The stable phases are indicated using solid lines and dotted lines for the
meta-stable phases. L is for liquid which is the melt of the solid. Tm is the melting point.12
Transformation from the metastable polymorph to the stable polymorph is mainly
via four routes: vapor, melt (liquid state), solid state, and solution state. Pharmaceutical
solids usually have a low vapor pressure and transition vial sublimation at ambient
temperature is not very common. When the crystal is heated to the melting point,
crystallization to another form can happen during the cooling of the melt. Conversion in
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the solid state usually occurs in response to an energy input. For examples, mechanic
milling induces crystal defects or an amorphous phase which are higher energy spots that
can promote nucleation to the more stable form. Compaction force during tableting
process can also cause polymorphic conversion. Heating the metastable form greatly
increases the molecular mobility to trigger recrystallization which can be determined by
DSC. The thermal events prior to the melting in a DSC thermogram are indicative of the
nature of polymorphic transformation.12-14 The conversion can also take place when the
metastable form is in contact with solution15 or moisture16 due to the solubility difference
between the two solid forms. The metastable form dissolves into the solution to reach the
solubility, which would be supersaturated with respect to the stable configuration. When
the supersaturation level is high enough, nucleation of the stable form commences. This
solution induced transition is referred to as solution-mediated phase transformation
(SMPT).17,18 The presence of the solvent does not change the thermodynamics and
stability relationship unless a solvate/hydrate forms with the solvent. However, owing to
the much higher mobility in the solution state than in the solid, the transformation to the
stable phases is much faster.
SMPT is the most relevant solid form conversion mechanism when considering the
drug dissolution into the aqueous medium in vivo. It not only describes the phase
transformation from a metastable form to the stable form, but also that from an
amorphous solid to a crystalline solid19 and from a salt to its parent20 or from co-crystal to
another co-crystal.21 For poorly water-soluble compounds for which the absorption in
vivo is highly dependent on drug concentration (dissolution rate or solubility-limited
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absorption), conversion to a thermodynamically more stable form is detrimental to
bioavailability and performance of the final drug product.
Crystallization Inhibition by Polymers
As stated previously, APIs are predominantly crystalline solids manufactured through
crystallization from solutions. Crystallization in solution occurs under conditions of
supersaturation with the first step being nucleation followed by crystal growth. As shown
in Figure 7, crystallization includes two processes: nucleation, and crystal growth after
nucleation. The mechanism of nucleation is divided into primary and secondary (induced
by crystals only) nucleation with the primary route further categorized into homogenous
and heterogeneous nucleation. Homogeneous nucleation is driven by concentration
fluctuations in a multicomponent fluid systems at the limit of Gibbs free energy stability
(spinodal decomposition), which is not a common event.22 Heterogeneous nucleation is
induced by foreign surfaces such as impurity particles or even glass walls which are
ubiquitous. The large sale crystallization of APIs is often done by secondary nucleation
where seed API crystals are added deliberately to induce faster crystallization and to
control the polymorphism.
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Figure 7. Crystallization from solution. Reproduced based on reference.22
However, the situation changes when the API enters the formulation development
phase, where particle size control and crystallization inhibition become the central focus.
Poorly soluble compounds often require an enabling technology to deliver, including salt
formation, lipid based formulation delivery systems, amorphous solid dispersions and
nanotechnology. Without exception, these formulations are metastable when
administered orally or by injection. Salt in water could disproportionate into the parent
drug plus the counter ion depending on the pH, and the drug molecule could crystallize
into less soluble parent crystals. Lipid based formulations as well as amorphous solid
dispersions upon dilution or dissolving could quickly reach high supersaturation
concentration, a driving force for crystallization. Nanoparticles can also be unstable in
aqueous solutions due to particle aggregation and size growth which threaten the
formulation performance. Even for less insoluble compounds, particle size growth is a
problem in formulating a pharmaceutical suspension common for ophthalmic or pediatric
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use. APIs used in suspension formulations are milled by crushing and grinding
operations, yielding particle surfaces with higher free surface energy. These particles
have a tendency of growing or knitting together to form a hard cake, causing difficulties
in re-suspending and producing a gritty texture unsuitable for topical, especially
ophthalmic, applications.23 Thus, inhibiting crystallization is an important task in
pharmaceutical formulation development.
Nucleation Theory
Before going into crystallization inhibition, it is necessary to understand the basics
of nucleation and crystal growth. Although crystals are ubiquitous, they have an
accidental nature to them.24 The molecules located in the internal lattice have a lower
chemical potential (µ) and are more stable, while those on the surface are coordinated
with fewer neighbors and thus they have a higher chemical potential (µ) and are less
stable. Assuming a tiny crystal with a radius, r, which is comprised of N interior
molecules (Nint) contributing to the stabilization of the tiny crystal, the stabilizing free
energies equal to

. The volume of the interior crystal is

by assuming

spherical nuclei. Correspondingly, the N surface molecules with the surface area of
4

will contribute to the destabilizing free energy by

. The tiny crystal

can only survive if the free energy of the interior molecules exceeds that of surface
molecules. Let G stand for the total free energy for a growing approximately spherical
tiny crystal, then we have:
4
3

4
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The minimal requirement for radius, r, is when G is minimized. The derivative of G gives
the following,24
0

4

8
2

Above equation indicates that the nucleus radius has to exceed two times the ratio
of the surface free energy over the interior free energy in order to be stable.
At this critical radius, the rate of nucleation, J, e.g. the number of nuclei formed per
unit time per unit volume, can be derived based on the Arrhenius reaction velocity
equation and the basic Gibbs–Thomson equation, as shown below.22

J

∆G
‐k T
Ae b

‐

Ae

16πγ3 v 2
3k 3b T 3 lnS 2
∆

Where A is the pre-exponential factor (the total number of collisions),
probability of any collisions that lead to the reaction,
the absolute temperature,

is interfacial tension,

is the

is the Boltzmann constant, T is

is the molar volume and S is the

supersaturation defined as the ratio of drug concentration over the crystalline solid
solubility. It is evident that the nucleation rate is a complex process affected by many
factors. At a given T, increasing S will increase the nucleation rate. A plot of J vs S at
natural log scale will indicate an initial linear increase but J becomes extremely fast when
some critical level of S is exceeded.22 Higher temperature increases the nucleation rate as
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well. J is also affected by A, the total number of collisions, which is expected to increase
with higher temperature and drug concentration. Therefore, an increase in both S and T
will increase the nucleation rate. Nucleation is the rate limiting step in crystallization.
Following the birth of nuclei, crystal growth may proceed rapidly.
Crystal Growth
Crystal growth has been described by several theories.25 The surface energy
theories, which have been almost entirely abandoned, are based on the assumption that
the total free energy of a crystal would be a minimum. The diffusion theories assume that
solute molecules are deposited continuously on a crystal surface at a rate proportional to
the concentration gradient between the bulk solution and the crystal surface. It is thus
considered a reverse process of crystal dissolution. The mathematical treatment is
therefore very similar to other mass transfer processes:

The crystal growth rate,

, is proportional to the overall crystal growth coefficient,

KG, the crystal surface area, A, and the driving force for diffusion,

where Cb is

the bulk concentration and Ci is the concentration at the crystal surface. The exponent g is
the overall process order. When g = 1 (first order), KG will be defined by
where kd is the diffusion coefficient of mass transfer and kr is the rate constant for surface
integration. This indicates that crystal growth is a two-step process, the first being the
diffusion of the molecules to the crystal surface and the second being the integration of
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the molecules into the crystal layer. If integration is fast, then the crystallization is ratelimited by diffusion. If the diffusion is fast, then integration becomes the rate limiting
step.
Adsorption-layer theories, on the other hand, assume that crystal growth is not a
continuous process; rather it is taking place by adsorption, growing layer by layer. There
will be a loosely absorbed layer of molecuels on the crystal surface, which will link into
the lattice in positions where the attractive forces are the greatest. Before the next layer
commences, a monolayer island nucleus is created. This is called two-dimensional
nucleation. The mathematical equation for the velocity of the two-dimensional nucleation
∆

is

which was developed similarly as the classical nucleation

theory described above with the letters having the same meanings. Similar to nucleation
rate, the crystal growth rate is faster when increasing temperature and supersaturation
levels.
Crystallization Inhibition by Polymers
It has been known as early as 1958 that polymers can be added to pharmaceutical
suspensions to increase viscosity and thus, to retard the overall crystal nucleation and
growth process.23 More recent pharmaceutical research in crystallization inhibition by
polymers has done mainly to meet the need to deliver poorly water-soluble compounds
by enabling technologies, particularly amorphous solid dispersions. A large number of
publications have been focused on how to screen polymers for making amorphous solid
dispersions of selected model compounds. As a comparison, studies with an objective to
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elucidate polymer–drug interaction mechanism are fewer. Simonelli et al., in 1970 first
described the underlying principles of using polymers to inhibit crystallization of drug
molecules.26 By studying sulfathiazole crystal growth at different concentrations and
different molecular weights of polyvinylpyrrolidone (PVP), Simonelli et al. established a
kinetic model to describe the dependence of crystal growth rate on the diffusion rate of
the polymer relative to that of the drug. The model entails that the polymer in solution
needs to reach the crystal surface from the bulk solution ahead of the drug molecules, and
the polymer concentration needs to be high enough to sufficiently cover the crystal
surface to cause inhibition of crystal growth. Their data also indicate that the polymer
must be tightly bound to the surface in order to be effective at low concentrations.
Therefore, the adsorption of the polymer to the crystal surface is of great interest. Many
models have been developed ever since27-31 for modeling polymer adsorption to a surface
using the Langmuir adsorption equation addressing polymer chain flexibility, molecular
weight, pH, rate of adsorption, etc. Recently, Alonzo et al.32 studied HPMC
(hydroxypropyl methylcellulose) for inhibiting nucleation and crystal growth of
felodipine. In the presence of HPMC, the crystal growth of felodipine shifted toward an
integration-controlled mechanism from a diffusion-controlled mechanism.
Based on these mechanistic studies, it was believed that the adsorption of a large
linear polymer molecule is due to the binding of particular sites; the remainder of the
chain projects into the aqueous phase as tails (the ends of the polymer) or loops (the
middle of the chain), as envisioned in Figure 8. The strong adsorption is due to the
collective energies of many binding sites on the polymer.28 Clearly, more studies are
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beneficial to understand exactly how the long polymer chain interacts with a crystal
surface and which energy forces are involved in the adsorption. This will also help to
understand the selectivity of the polymer adsorption to drug molecules which may lead to
better ways to design the most efficient formulations.

Figure 8. Schematic of the configurationally change of adsorbed polymers with
increasing surface concentration.27
Molecular Dynamics Simulation
The first molecular dynamics (MD) simulation of a macromolecule of biological interest
was published in 1977,33 which changed the early view of proteins as relatively rigid
structures to a dynamic model. Since then, computational biology, particularly MD
simulations, have advanced rapidly in methodology and applications in parallel with
advances in computing power and simulation programs.34-36
Molecular modeling takes its roots from quantum mechanics (QM) which is based
on the solution of the Schrödinger wave equation.37 The wave equation describes the
motions of the electrons and nuclei in molecular systems. The 3D molecular structure,
molecular energies and many associated properties can be calculated by this equation.
However, the level of complexity to solve the Schrödinger equation is prohibitive in
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calculating a large system. To simply the calculation, Born and Oppenheimer made an
approximation by assuming the nuclei, which are much heavier than the electrons, are
fixed on the time scale of electronic vibration.37 There are primarily two QM methods
derived from the Born-Oppenheimer approximation: ab initio QM and semi-empirical
QM. The former is more rigorous than the latter; therefore it requires more computational
time. DFT (density function theory) is a variation of ab initio QM which improved the
calculation efficiency. Nevertheless, all of the QM methods are still very demanding in
terms of computational expenses and time, therefore they are not practical in calculating
larger systems, such as proteins. This led to the development of an alternative approach –
the molecular mechanics (MM).
The MM model treats all of the atoms as spheres connected by springs representing
bonds. Internal forces experienced in the model structure are described using simple
mathematical functions38 forming the potential energy function. MD simulation uses
molecular mechanics (MM) models to numerically solve Newton’s equations of motion,
thus allowing atomic or molecular motions to be observed with respect to time,38 and
providing the ultimate details of motional phenomena.
Potential Energy Function
The success of a MD simulation is highly dependent upon a suitable potential
energy function which is called a force field. The current study uses the CHARMM
(Chemistry at HARvard Molecular Mechanics) force field39 which has been separately
parameterized for proteins, nucleic acids, lipids, and carbohydrates, making it highly
versatile and widely used. The potential function,

), is a sum over individual terms
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representing the internal and nonbonded contributions as a function of the atomic
coordinates, as described in the following equation.38

Equation 1. Potential energy function of CHARMM27.38
As summarized in Table 1, each term in Figure 1 represents a simple functional
form and describes an intermolecular or intramolecular force within the system. These
terms are additive in nature, resulting in the potential-energy function to describe the
energy landscape of the system from a single set of atomic coordinates. The force
constants for bonds (Kd), angles (Kθ and KUB), dihedrals (Kχ) and improper dihedrals (Kφ)
are empirically determined. The reference (or equilibrium or ideal) values for bonds (d0),
angles (θ0 and S0) and dihedrals (φ0) were determined by both experimental techniques
and quantum mechanical calculations which are included in the force field in the MD
simulation programs. Besides the CHARMM force field, there are others available, such
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as AMBER (preferred by nucleic acid modelers), ECEPP (dihedral angle program for
proteins), and GROMOS, OPLS, CFF, and SIGMA.37
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Table 1. Individual Terms in CHARMM27 Potential Function.
Term

Function
Bond stretching.
Kd: bond length force constant.
d: bond length.
d0: reference value of bond length.
Angle bending using 1,3-nonbonded
interactions.
KUB: Urey-Bradley force constant.
S: Urey-Bradley.
S0: reference value of Urey-Bradley.
Angle bending.
Kθ: bond angle force constant.
θ: bond angle.
θ0: reference value of bond angle.
Dihedral (torsion angle) motion.
Kχ: dihedral angle force constant.
χ: dihedral angle.
n: periodicity of the dihedral angle
δ: phase shift
Improper dihedral motion (out of plane
bending).
Kφ: improper angle force constant.
φ: improper dihedral angle.
φ0: reference value of improper dihedral
angle.
Nonbonded interactions. Coulombic
equation for the electrostatic energy and
Lennard-Jones potential for van der
Waals (VDW) energy.
ϵij: Lennard-Jones well depth.
: distance at which the LennardJones potential is zero.
rij: distance between atoms i and j.
qi: partial atomic charge of atom i.
qj: partial atomic charge of atom j.
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Newtonian Molecular Dynamics
Under the influence of the force, particles in a system move according to Newton’s
equation of motion,

where F is the force exerted on the particle, m is mass of the particle, a is its acceleration,
v is the velocity, t is the time, x is the distance the particle moves and

is the gradient

of the potential function. The force, F, is the negative gradient (first partial derivative) of
to

the potential energy. The velocity of the particle can be obtained by integrating
give the following equation.

Similarly, integration of the velocity (

) give the following equation.

Combining of above two equations leads to the following expression,

which correlates the position of the particle to the acceleration a, the initial velocity
and the initial position

,

at time t. This means that if the initial position and the initial

velocity of the particle are defined, the position at a given time can be calculated because
the acceleration can be obtained from the derivative of the potential energy function with
respect to the particle position (

).

The initial positions are determined by the starting coordinates (e.g. crystal
structure). The initial velocities are typically set pseudorandomly from a Maxwell-
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Boltzmann or Gaussian distribution at a given temperature, which is accomplished by
many software packages.40
In simulation of a large system, the potential energy is a function of the atomic
positions of all the atoms in the system. Due to the complicated nature of this function, a
numerical integrator is needed. Among the numerous numerical algorithms available, the
Leapfrog/Verlet Algorithm is the most commonly used. The Verlet algorithm is based on
a Taylor series expansion. It uses the positions at time t and the velocities at time
∆

for updating both positions and velocities via the acceleration a. The equation to
∆

update velocity is
coordinates is

∆

∆

∆ . The equation to update the
∆

∆ .38

In practice, a successful MD simulation requires implementing many details, such
as obtaining appropriate parameters, coordinates and topology files, setting initial
conditions, selecting a program, acquiring high speed computers, and visualizing and
analyzing the large size data set, and so forth.
Applications of MD Simulations to Pharmaceutical Research
MD Simulation to Study Drug Dissolution
MD simulation of drug crystal dissolution into anaqueous medium has not been
reported prior to 2013.41 However, there have been several dissolution simulations of
non-drug crystals in the literature. The earlier work was on inorganic salt crystals (i.e.
NaCl) by Ohtaki and his co-authors in the late 1980’s.42-44 The motivation to study NaCl
was that sea salt (i.e. NaCl) crystal dissolution is one of most crucial dissolution process
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in atmospheric chemistry. Due to the limitation of computational resources, these earlier
studies simulated very small crystals in a small water box. The first study43 reported in
1988 was a 7 ps long MD simulation of a 32 NaCl molecule crystal in 216 water
molecules to calculate ion–ion, ion–water and water–water interactions. Based on their
results, chloride ions from the five corners dissolved but the sodium ions did not. A year
later, a follow-on study42 simulated the dissolution of the NaCl (111) face which was
covered with chloride ions only and the (–1–1–1) faces which was with the sodium ions
only. Similarly, 28 NaCl molecules were put into the water box containing 189 waters
which was simulated for 7 ps. This second simulation repeated the previous results in that
only the chloride ions dissolved and sodium ions remained on the crystals. It was
hypothesized that the repulsive forces arising between the chloride ions and the water
molecules push the chloride ion out from the crystal surface as they possess a smaller
hydration energy than the sodium ions. These authors reported another study44 in 1993
that expanded the salt list to include many alkali halide crystals (LiCl, NaCl, CsF, KCl,
NaF, and KF). Within 12 to 20 ps, the anions in the LiCl, NaCl and CsF crystals have
dissolved but none of the cations have. Interestingly, for crystals of KCl, NaF and KF
having similar size of cations and anions, no ions have dissolved within 20 ps. Using
anion solution X-ray diffraction, NaCl and KCl were found to form 1:1 ion pairs in
solution. On the other hand, KF and CsF solutions formed ion clusters larger than 1:1 ion
pairs. It appears no conclusion could be made based on these results. In 2011 (eight years
later), Liu eta al. did a simulation on NaCl dissolution in water45 using the state-of-the-art
ab initio molecular dynamics and free energy sampling techniques. Their results shed
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some light on the anions preferential initial dissolution. The crystal was comprised of 3
layers of NaCl covered with a 15 Å thick water layer. The simulation was performed for
a total of 1 µs with classical force fields [molecular mechanics (MM)] and a separate 0.6
ns of ab initio QM (quantum mechanics simulation). In the force-field MM description,
the Born–Mayer–Huggins potential was used for NaCl and the TIP3P model was for
water. For the QM description, density-functional theory (DFT) with the PBE27
exchange–correlation function was used. They showed that NaCl dissolution is a complex
multi-step process triggered by the initial departure of Cl ions from the lattice followed
by the departure of Na ions. A well-defined intermediate state was identified in which the
departing Cl ion is partially solvated and still retains contact with the crystal. Based on
the calculated QM free energy barriers, the initial rate of Cl ions dissolution will be about
1000 times larger than that of Na ions. The departure of Cl ions disrupts the surface and
leaves a Na ion in an almost fully solvent-exposed location, primed for subsequent
dissolution. The better results from the 2011 study seem related to the use of more
advanced simulation methods including a different force field, ab initio MD, and a longer
run time. Nevertheless, the very early studies by Ohtaki and his co-authors did indicate
that Cl ions should departure first in NaCl crystal dissolution. This reminds us of the
remark Martin Karplus made in his review article in 2002, “The conceptual changes
resulting from the early studies make one marvel at how much of great interest could be
learned with so little—such poor potentials, such small systems, so little computer
time.”46
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The simulation of salt crystal continued in 2012 with KCl dissolution. The study
employed density-functional theory (DFT) calculations and molecular dynamics studies
using the GROMACS force field.47 In the MD simulation, three crystal surfaces each
with 105–120 KCl molecules were simulated in about 3000 waters for 2.5 ns. The
observations were similar to the NaCl study in 2011. The DFT calculation indicated the
departure of Cl ions was before the Na ions and has been found to be more significant
from the edge of the KCl crystal. At least four water molecules were found to be
necessary to initiate the separation of the ions from KCl crystal. The observation from
MD simulation indicated different ion departure profiles with the three different KCl
faces.
Simulations were also done on poorly water-soluble salts. In 1999, Parker and
coworkers48 modeled different stepped surfaces of a calcium carbonate crystal with a
small amount of water using a molecular dynamic simulation. This process represents the
aqueous corrosion which is of importance in geological science. By simulating a
monolayer of water on the calcium carbonate surface, they found that water has a
stabilizing effect causing slower dissolution than that in vacuo. The same authors
conducted another MD simulation study49 in 2006 on the interaction of two solid
surfaces, namely the (001) hematite (α-Fe2O3) and (104) calcite (CaCO3) surfaces in
contact with aqueous electrolyte solutions containing different concentrations of NaCl. A
few layers of water were added and the simulation lasted for 1 ns. They observed a
characteristic double layer of water at neutral surfaces and that the charge distribution
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oscillates into the bulk. The presence of dissolved ions was found to make a small but
significant reduction to the dissolution free energies.
MD simulation on organic molecule dissolution has been rare before 2013 and only
two papers were found. In the study reported in 2005, a flat crystal surface of urea (001)
was built and simulated using the GROMACS force field in the presence of water to
monitor the dissolution and subsequent recrystallization.50 They observed that at 298 K
the dissolution proceeded until two layers of urea were completely dissolved. At this
point, the surface layer concentration was calculated as 2–7 M which is still below the
saturation solubility of 11 M, but it is probably high enough to slow down the dissolution
rate to the point that it is no longer measurable by MD simulation. They then decreased
the temperature to 260 K and simulated a further 38 ns. After a short induction period,
formation of a nucleus on the crystal face was observed which continued to grow until a
new layer was formed on the crystal surface. The supersaturation on the surface for
nucleation was assumed due to the solubility difference between 298 and 260 K. The
paper did not discuss what the solubility of urea is at 260 K which may not be measurable
in frozen water (ice).
The second organic molecule dissolution was published in 2011 by Hayakawa and
co-authors.51 The dissolution process of cellulose triacetate (CTA) II crystal was studied
in dimethyl sulfonamide (DMSO). The nanocrystal consisting of 18 CTA chains in an
8 × 8 × 8 nm box with DMSO molecules was simulated for 9 ns using the CHARMM
program and carbohydrate force field. As illustrated in Figure 7, one CTA chain detached
from the crystal surface and entered the DMSO solution at 9 ns. The three types of H-
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bonds with varying degrees of bond strength responsible for forming the crystal all
disappeared during the dissolution. The two stronger H-bonds provide the major
resistance to solvation with DMSO based on the energetic calculation.

Figure 9. MD Simulation of dissolution of cellulose triacetate II nanocrystal into DMSO
at time 0 (a) and 9 ns (b) (from Figure 2 of reference 51).51

52

37

Several papers emerged in 2014. Toroz et al. reported MD simulations of two
polymorphs of para-aminobenzoic acid (which is not a drug per se but structurally similar
to some drugs) at temperatures of 0, 50 and 100 °C for 5 ns. The crystals were solvated
using TIP3P model but the water box size was not described. The two polymorphs, α
form and β form are enantiotropically related, with the transition temperature (Tt) at 13.8–
16 °C. Below the Tt the β form is more stable, and above the Tt the α form is more stable.
Thus, simulation at 0 °C should identify β form as the stable form, while at 50 °C or
100 °C should identify the α form. Their results showed that at 0 °C both forms remained
as ordered crystal, but at 50 °C the two forms became partially disordered and 100 °C
both lost long range order. The stability of the nanocrystals appeared to be an issue, and
will need more investigations in the future.
In summary, the practice of using MD simulation to study crystal dissolution has
been demonstrated in the literature; and the methodology has gradually improved over
the last two decades. There have been very few reported studies limited to small salt
crystals and two organic molecules (urea and cellulose). There have been no reported
studies on drug crystal dissolution. Hence, it is necessary to establish MS simulation of
drug crystal dissolution as a special focus in pharmaceutical research considering that (1)
the small salt crystals or large molecular weight cellulose crystals are structurally
different from the majority of organic drug crystals, and (2) the purpose of drug
dissolution is to understand the effect of surface area, polymorphism, polymorphic
transition, supersaturation level, dissolution media, etc. which are very different from the
dissolution studies done in the above surveyed disciplines.
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MD Simulation to Study
Polymer Interaction with Drug Crystals
There are quite a few papers in recent years reporting the simulations of the
interaction of polymers with drug or drug like molecules in solution. The purpose of
these studies was to understand or identify polymer systems for polymer based drug
delivery (i.e. polymeric nanoparticles), therefore, single or multiple drug molecules rather
than a drug crystal was simulated with the polymers.53-57 For example, in 2011, Subashini
et al.57 conducted MD simulations to model drug uptake by polymers. The structures of
three drugs and six polymers at decamer or hexamer length were built with
HYPERCHEM® software. MD Simulations were performed in 11,300 water molecules
using the GROMACS forcefield for 300 ps at 300 K, and the interaction energy between
various drugs and polymers was calculated. They found the interaction energies were
correlated with the experimentally observed drug uptake values. In another example,
Kasimova et al.55 in 2012 studied how four different lipophilic drugs (cyclosporine A,
griseofulvin, ketoconazole, and quercetin dihydrate) were loaded into a polymeric micelle
consisting of six chains of amphiphilic copolymer PEG−hexPLA (built at molecular
weight of 5000 g/mol). The four drugs and monomers were parameterized using the
general AMBER force field (GAFF), and simulated in TIP3P explicit water for 10 ns
after equilibration in vacuum. The interactions between the PEG−hexPLA and the drugs
were evaluated by Flory−Huggins interaction parameters which are routinely used to
measure the miscibility of two polymers or polymer with other materials. The
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Flory−Huggins parameters calculated from the MD simulations were consistent with the
experimentally measured Flory−Huggins parameters.
MD simulations with the objective to study drug crystallization inhibition by
polymers have also been reported. They can be divided into two main areas: (1) polymer–
drug interactions in amorphous solid dispersion systems which primarily investigated the
solubility or miscibility of the drug and polymer(s) in the solid state,58-63 and (2)
polymer–drug interactions in crystal systems to investigate crystal growth inhibition in
the solution state.64-66 In the former, the rationale is that if the drug is fully dissolved in
the polymer or miscible with the polymer, then the crystallization of the amorphous drug
in the polymer matrix will not take place. Described here are the two representative
papers. Gupta et al.60 performed MS simulations using the COMPASS force field to
predict the miscibility of indomethacin with polyethylene oxide, sucrose and glucose
through the calculated cohesive energy and the solubility parameter. An amorphous cell
with 60 indomethacin molecules with either 72 sucrose molecules, or 144 glucose
molecules or 14 chains of polyethylene oxide (PEO) each containing 30 monomer units
were made into a 3 × 3 × 3 (nm) box. The system was equilibrated for 2 ns followed by a
500 ps production simulation. The MD simulations predicted indomethacin to be miscible
with polyethylene oxide and to be borderline miscible with sucrose and immiscible with
glucose. The MD simulation of indomethacin with PVP by Xiang and Anderson63 was
done differently. Five assemblies with varied indomethacin and PVP compositions with
parameters assigned from the Amber force field were first equilibrated in their molten
states and cooled to generate amorphous glasses. Prolonged aging dynamic runs (100 ns)
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at 298 K were then carried out, from which the solubility parameters, the Flory–Huggins
interaction parameters, and associated hydrogen bonding properties were obtained. It was
found that inter-drug molecule H-bonding was decreased and replaced by drug–polymer
intermolecular H-bonding. The calculated Flory–Huggins interaction parameter was able
to predict the miscibility accurately when compared to experimental results.
In the second area involving polymers to inhibit drug crystal growth in aqueous
media, there are only three published studies. Zhu et al. simulated the interaction of
several additives such as hydroxypropyl methylcellulose (HPMC) in water with crystal
surface of fenofibrate66 and griseofulvin.65 A short HPMC chain (five repeating units)
was constructed and placed into a small water box (1500 water molecules) with the
simulation carried over a short duration (600–800 ps). The simulated binding energies
between the additives and crystal surface were correlated with the experimental results
when these additives were found to reduce the particle size of recrystallized griseofulvin.
In 2012, Yani, Chow and Tan reported64 a 400 ps MD simulation of large polymers (225
monomers for PVP and 62 for HPMC) with different crystal phases of salbutamol sulfate
in a vacuum. Hydrogen bonding between PVP and salbutamol sulfate, which was ~40%
of the total binding energy, was thought to dominate in prohibiting crystal growth.
Outside of the pharmaceutical area, simulations of polymers with crystals were
reported in recent years. The collection of literature includes the simulation in dry state of
the (poly(octadecyl acrylate)) incorporating into the surfaces of a paraffin crystal (which
is a kind of liquid crystal) to inhibit crystal growth,67 the simulations of 6 polymers
(which have not been used as pharmaceutical excipients) with mineral crystal
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hydroxyapatite which identified the importance of the carboxyls at the ends of the
polymer chains,68 and a similar study of other sets of polymers with hydroxyapatite
crystal69 and with calcite.70
In summary, in the second area (polymers inhibiting pharmaceutical crystal growth
in solutions), very limited MD simulations have been done under only limited conditions
(short runs, in vacuum or in small water box with short run times). Thus, this area was
identified as a gap to motivate future research.

CHAPTER TWO
STATEMENT OF RESEARCH
The literature review identified several areas in pharmaceutical field which we believe
can benefit from the application of molecular dynamics simulation. The areas of focus for
this dissertation include drug crystal dissolution, polymorphic transition and drug–
polymer interactions. The hypothesis is that MD simulation can potentially help
understand these pharmaceutical mass transfer processes in aqueous media at the
molecular level. This greater understanding could lead to better control over drug
dissolution and polymorphic transformation.
Drug Crystal Dissolution
Understanding drug dissolution has been a subject of extensive pharmaceutical research
due to its impact on drug absorption and therapeutic effect in humans. Despite the many
mathematical models and well-established experimental methodologies, understanding of
how a drug molecule detaches itself from solid phase (mostly crystalline) and enters into
solution is quite poor for the most part. The purpose of our research is to:
1. To develop and establish methodology in building crystal structure files using
acetaminophen as the model drug. Acetaminophen was chosen because of its
relatively simple chemical structure for obtaining the parameters, and the
interesting polymorphism which is the second focus of this dissertation.
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2. To conduct dissolution simulation in water containing 0.15M NaCl at 37 °C, a
condition relevant to in vivo.
3. To analyze how each molecule dissolves into water in order to gain a

molecular level dissolution profile and the energetics involved in the
dissolution.
Polymorphic Transition
Acetaminophen Form II is well known to undergo a fast conversion to the stable Form I
in solution. Since the conversion occurs in the presence of solution, it was assumed that
the solution-mediated polymorphic transformation is the responsible mechanism for such
a conversion. However, the details of the transformation have not been understood, and
the reasons for such fast conversion are mostly unknown. The motivation is to elucidate
the mechanism of the conversion by conducting the following studies.
1. Determine the thermodynamic driving force for the Form II to Form I
transformation through experimental methods and MD simulation.
2. Identify the reason for generating the supersaturation necessary for nucleation
using MD simulation and/or experimental methods.
3. Explain the fast kinetics of Form II to Form I conversion
Drug–Polymer Interaction
The ability of polymers to inhibit crystallization of drug molecules has been the subject
of intense research in recent years. Polymers are used to stabilize a metastable solid form
in formulations, i.e. amorphous solid dispersions and nancrystals to deliver poorly watersoluble small molecular drugs. Polymers also are used to maintain supersaturation during
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dissolution of enabling formulations for maximizing formulation performance. Finally,
polymers can play an important role in modifying the crystal habit during solution
crystallization. In this dissertation, we selected to study a polymer drug system reported
to have crystal surface specific interactions with the polymer. The objectives are:
1. To build and obtain the hydrated PEG-b-PLA structure.
2. To develop procedures to build structural files of tolazamide crystals with a large
crystal surface area.
3. To conduct MD simulations on the interaction of the hydrated polymer with
several crystal surfaces in water and to compare these with experimental results.
4. To understand the mechanism of interaction by calculating and analyzing the
interaction energies.

CHAPTER THREE
MOLECULAR DYNAMICS OF DRUG CRYSTAL DISSOLUTION:
SIMULATION OF ACETAMINOPHEN FORM I IN WATER
Abstract
In order to gain a molecular level understanding of drug dissolution into aqueous media,
we report the first molecular dynamics (MD) simulation of a drug crystal dissolving. The
simulation was performed for acetaminophen crystal Form I dissolving in 0.15 M
aqueous NaCl solution at 37 °C. The 10 ns simulation revealed interesting details of the
dissolution process. Dissolution of the molecules from the crystal surface is far from a
random process. On the contrary, the order of which molecules enter the solution depends
on their initial positions in/on the crystal. Molecules located on the corners and edges
dissolved first followed by those located on (100), (010) and (001) surfaces with slight
variation. This corner and edge effect that has been observed by our real dissolution
experiment conducted under polarized light microscope was successfully predicted at the
molecular-scale by the MD simulation. Further analyses revealed the underlying
mechanism: the differences in the molecular interaction energetics between the drug and
water molecules. The molecules located on corners and edges of the parallelepiped
crystal are not as tightly bound to their surrounding neighbors as those located in other
positions, but they are more strongly interacting with the surrounding water molecules.
The extent of molecular release is strongly correlated with the interplay between
45
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interaction forces with solvent molecules and with other drug molecules in the crystal
lattice. These findings, especially the significant “corner and edge effect”, will help us
gain additional fundamental understanding in the relationship between dissolution rate
and particle size and morphology, and thus are very relevant in the context of particle size
reduction in delivering poorly water-soluble compounds. This study has also
demonstrated that MD simulation is a powerful tool in studying dissolution phenomena.

Key words: molecular dynamic simulation; crystal form; dissolution; corner and edge
effect; electrostatic and van der Waals; acetaminophen
Introduction
The first important step in drug absorption from oral solid dosage forms is dissolution, a
process by which the drug molecules detach from the solid particles and enter into the
surrounding gastrointestinal (GI) milieu. Thus dissolution rate is of fundamental
importance in pharmaceutical dosage form design. Over the years, understanding drug
dissolution has been a subject of extensive pharmaceutical research.6,71-75 Despite the
many mathematical models and well-established experimental methodologies,
understanding of how a drug molecule detaches itself from the solid phase (mostly
crystalline) and enters into solution is quite poor for the most part. One possible reason is
that the dissolution mechanism, at a molecular level, is difficult to deduce even with
highly sophisticated experimental approaches. In this context, computational methods,
molecular dynamics (MD) simulation in particular, are a powerful tool that has the
potential to help discern patterns and add insights that are otherwise difficult to gain.76
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In biological sciences, MD simulation has contributed significantly with manifold
applications relating to proteins,77-79 nucleic acids80-82 and lipids.83,84 For example, it
changed the earlier view of proteins being rigid molecules and replaced those notions
with a dynamic structural model with constant motion that is vital in their biological
functions.85 In drug discovery, MD simulation plays an essential role in drug design and
structural optimization.86-89 Application of MD simulation in other aspects of
pharmaceutical sciences is also emerging although publications are limited to date.
Recently, Xiang and Anderson90-93 applied MD simulation to the study of lipid bilayers
and gained mechanistic understanding of solute partitioning and transport across
biomembranes. They have also studied the mobility of a small peptide, Phe-Asn-Gly, in
amorphous glasses of poly(vinyl pyrrolidone) (PVP) containing small amounts of water
and ammonia using MD simulation. They were able to observe glass transition, aging
processes, and the associated structural and dynamic properties of PVP and the embedded
peptide.24 Li and coauthors94,95 simulated etching patterns on the acetaminophen
monoclinic (010) crystal face by calculating the energies associated with molecular
detachment, surface diffusion, and additive molecule adsorption using a refined Monte
Carlo simulation model. Fuelled by the dramatic increases in computing power in recent
years, the use of computational methods in pharmaceutical sciences has showed a
growing trend.64,96,97 However studying dissolution of organic molecules, such as drugs,
using this methodology has not yet been reported. Parker and coworkers48 modeled
different stepped surfaces of calcium carbonate crystal using molecular dynamic
simulation. By simulating a monolayer of water on the calcium carbonate surface, they
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found that water has a stabilizing effect causing slower dissolution than that in vacuo.
Dissolution of sea salt crystals (NaCl and KCl) into water was also simulated in the early
1980’s by molecular dynamics simulation42-44 and more recently by quantum mechanics
simulations.45,47 The scope and purpose of these studies are very different from the
dissolution concept applied in pharmaceutical fields. The aim of this work is to
investigate the dissolution behavior and energetics of key stages in drug molecule
dissolution using MD simulations. Acetaminophen (designated as APAP hereafter), a
widely used analgesic and fever reducing medicine, was used as a model drug. Its initial
dissolution into biologically relevant aqueous medium was studied by MD simulation, the
simulated data were analyzed by interaction energy calculations, and key results from the
simulation were verified experimentally.
Experimental
Material
Acetaminophen anhydrous polymorph I (Form I) with high purity was purchased
from Sigma (SigmaUltra, lot 116K0124), and was used in solubility studies as received.
Deionized, distilled water for preparing the dissolution medium (0.15 M sodium chloride
in water) was purified to 18.2 mΩ/cm resistivity by passing distilled water through a
deionizer/charcoal filter (Milli Q academic model, Millipore Corp., Bedford, MA).
Sodium chloride used met ACS Reagent specifications.
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Solubility Measurement
Equilibrium solubility of acetaminophen Form I was measured in an 0.15 M
aqueous solution of sodium chloride at 37 °C. Sufficient solid was added to 3 mL of
medium in six replicates. The suspensions were equilibrated for >2 days at 25 rpm on an
end-over-end tumbler, model 30-1200 (Vankel, Cary, NC), in a water bath set at 37 °C.
After equilibration, the saturated solution was collected by filtration (13 mm Acrodisc®
syringe filter with 0.45 µm GHP membrane, Pall Life Sciences, Ann Arbor, MI), at least
1.5 mL of the filtrate was discarded, and the last 0.5 mL was collected. The filtrate was
then immediately diluted into HPLC mobile phase and analyzed by HPLC using a fivepoint external standard curve. The average concentration of the saturated solutions was
reported as the solubility at 37 °C.
Theoretical Methods
Building the Crystal
The single crystal structure of acetaminophen Form I, HXACAN01,98 was retrieved
from the Cambridge Structural Database (Cambridge, UK). The unit cell comprises four
APAP molecules. Using the Mercury software (Mercury 2.2, CCDC 2001-2008), a
crystal lattice was built by repeating the unit cell at each of the three dimensions for four
times. The resultant crystal, referred to as APAP1 4 x 4 x 4, consists of 64 unit cells and
256 APAP molecules. The size of this crystal is 51.72 × 37.60 × 28.40 Å, about 4.6 nm in
diameter. The shape of the crystal is parallelepiped in the monoclinic crystal system.
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Preparing the Crystal for Simulation
The 4 x 4 x 4 crystal constructed above was prepared using Visual Molecular
Dynamics software (VMD, version 1.8.7, August 2009).99 First, the structure file of the
crystal was built using the Automatic PSF Builder function from the input of the Mercury
file and the APAP topology file. The topology and atom types for the CHARMM2739
force field for APAP were obtained by comparison with similar molecules already in the
standard topology file. Second, a water box was built to surround the crystal. The water
box (containing 0.15 M sodium chloride to mimic the ionic strength of biological fluid)
extends 40 Å on each side of the crystal to amount to 58622 TIP3 (water) molecules. The
size of the water box is 131.7 × 117.6 × 108.4 Å3, which equals to 1.5 × 10-18 milliliters.
The ratio of water molecules to the NaCl molecules in the system is 370 to 1.
MD Simulation
The computer code used for the MD simulations was the parallel, scalable MD
program NAMD version 2.5.100 Periodic boundary conditions were used. The cutoffs for
nonbonding (van der Waals and electrostatic) interactions were 12 Å. The switch distance
was 10 Å, and a 1.0 1–4 scaling factor was used. The 4 x 4 x 4 crystal in the water box
was first subjected to energy minimization (6000 steps) followed by slow heating from
10 to 310 K over 30000 steps. The pressure on the system was equilibrated for
10000 steps using a Langevin piston. The system was then allowed to equilibrate for
30000 steps at constant temperature (310 K) and pressure (1 atm) before production data
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was accumulated. Production simulations (10 ns) were performed at constant volume and
temperature.
Calculation of Interaction Energies
Interaction energies were calculated using algorithms of the van der Waals and
electrostatic energies and the NAMD program.100 These calculations were performed for
specific APAP molecules with their surrounding APAP molecules, water molecules, and
Na+/Cl-, for defined groups of APAP molecules with the surrounding water molecules
within 4 Å. Because partial charges exist in any atom due to the different
electronegativities of the atoms, the potential function used in the molecular dynamics
simulation considers the partial charge in every atom even when the molecules are
neutral (such as APAP). The electrostatic interactions, including ion–dipole interactions
and H-bonding, are calculated using these partial atomic charges (CHARMM potential
function39). The results of interaction energy calculations were analyzed using VMD.
Visualize Dissolution of APAP Crystals under
Polarized Light Microscope (PLM)
The purpose of the experiment is to observe whether the dissolution starts from
corners and edges. Acetaminophen crystals of sufficient size were prepared by
recrystallization from water according to reported procedures.101 The recrystallized solids
were found to be anhydrous Form I by powder X-ray diffractometry (model Ultima II D,
Rigaku Corp., Tokyo, Japan). The faces of the crystals were not indexed by single crystal
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X-ray diffraction since the observation will be focused on corners and edges. The crystals
were stored in a tightly closed jar with desiccants at room temperature until use.
A crystal (size of ~3 mm in length and 1.2 mm in width) was placed on a glass slide
under a polarized light microscope (model Eclipse E-600 POL, Nikon Corp., Garden
City, NY) with 4× magnification lens. Images were taken using MetaMorph imaging
system (version 4.6R8, Universal Imaging Corporation, Downingtown, PA). Drops of
dissolution medium (0.15 M sodium chloride in water) were added to completely cover
the crystal. Dissolution of the crystal was monitored visually by capturing images
periodically.
Results
Model compound APAP is a small molecular drug (molecular weight of 151.16 g/mol).
Its chemical structure is shown in Figure 10a. The drug is weakly acidic with a pKa of
9.5102 at 25 °C attributed to the phenol moiety. Therefore APAP is neither ionized at
physiological pH nor in a 0.15 M aqueous solution of sodium chloride, the dissolution
medium used in this study. In a 0.15 M aqueous solution of sodium chloride, the
equilibrium solubility of APAP Form I was measured to be 20.0 ± 0.2 mg/mL or
0.132 ± 0.001 M (n = 6) at 37 °C. The reported solubility under the closest conditions is
21.02 ± 0.13 mg/mL in water at 37 °C.103
APAP anhydrous Form I has a monoclinic structure98 with space group P21/a, and
a = 12.93 Å, b = 9.40 Å, c = 7.10 Å, α = β = 90.0° and γ = 115.9°. Each unit cell contains
four APAP molecules, as shown in Figure 10b. By four times repetition of the three-
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dimensional translation of the unit cell, the constructed 4 x 4 x 4 crystal assembly
comprises 256 APAP molecules with a size of 51.7 x 37.6 x 28.4 Å3 (Figure 10c). Of the
six surfaces of the crystal, two are (100) type, another two are (010) type, and the last two
are (001) type of surfaces. The water box consisting of a total of 58622 water molecules
as well as 0.15 M sodium chloride extends 40 Å from each side of the crystal to create a
water box size of 131.7 x 117.6 x 108.4 Å3 (Figure 10d). The size of the water box was
so designed that if the crystal were completely dissolved, the concentration would be
0.28 M, that is, about 2-fold of the solubility. Analogous to a physically performed
solubility measurement, extra solids were added to the medium, and the dissolution
process was monitored by MD simulation. At the end of 10 ns simulation, the APAP
concentration in the water box was about 40% of the solubility.
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Figure 10. (a) Molecular structure of APAP. (b) Unit cell of APAP anhydrous Form I
(dotted line indicating the two hydrogen bonds). (c) The 4x4x4 crystal of APAP
anhydrous Form I built by repeating the unit cell four times in all three dimensions,
viewed down crystallographic c axis. (d) 4 x 4 x 4 crystal of APAP Form I in the 131.7 ×
117.6 × 108.4 Å3 water box.
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Grouping of APAP Molecules
For the purpose of tracking the molecules that are released, the surface molecules
on the crystal were divided into seven groups based on structural insights and the
symmetry of the parallelepiped shaped crystal, which has eight corners, twelve edges,
and six surfaces. Figure 11 illustrates how the surface bound molecules are grouped. The
molecules located on the 8 corners are named as “corner group”. Similarly, the molecules
on the 12 edges (except for those in the corner group) formed the “edge group”. The
differences among the molecular orientation on the surfaces are significant; the two (100)
surfaces are made of APAPs with the phenol group pointing toward external water phase.
The two (010) surfaces have the methyl group exposed to the outside, and the molecules
on the two (001) surfaces form crossed structures. Further, the top layer of APAP
molecules on the (100) and (010) surfaces is completely exposed to water, but the second
layer right beneath appears to be partially accessible to water. On the (001) surfaces, on
the other hand, the APAP molecules are intertwined, forming a single surface layer
accessible to water. Therefore, besides the corner group and edge group described above,
other surface bound molecules are logically divided into five additional groups: (100)
layer 1 (top layer on the 2 surfaces of (100)), (100) layer 2 (second layer on the tow
surfaces of (100)), (010) layer 1 (top layer on the two surfaces of (010)), (010) layer 2
(second layer on the two surfaces of (010)), and (001) layer 1.

{100} Type

{ 100} T yp e

{010} Type

{ 010} T yp e

Corners and Edges

(100) and (010) Types

(001) types

Figure 11. Illustration of seven groups: (left) Circles indicate positions of corner group molecules; bars indicate positions of edge
group molecules. (middle) Surfaces of (100) and (010) types viewed down crystallographic c axis, both with layer 1 (bulky VDW
style) and layer 2 (smaller VDW style). (right) Surfaces of (001) type (viewed down crystallographic a axis).
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Observation of the MD Simulation
The crystal in the water box was first equilibrated to reach lower energy. Figure 12a
is the image of the crystal at the end of equilibration, which exhibits some interesting
features. First, the crystal remained intact preserving the overall three- dimensional longrange order as originally built. Second, each molecule moved around within limited
boundaries, representing vibrational and rotational movements of molecules in the crystal
lattice. Last, the molecules on outer layer appeared much more mobile than those located
deeper inside the crystal.
The simulation of dissolution was then initiated and continued for 10 ns. APAP
molecules gradually left the crystal and over time accumulated in the water phase. The
dissolved molecules display thermal motions. They move around within the water box in
a random manner, sometimes wandering back to positions close to the crystal surfaces.
Figure 12b,c shows snapshots of the system at 3 and 10 ns respectively. It is obvious that
with time the crystal became smaller, and the released numbers of APAP molecules were
increased. It is also noticeable that only the molecules located on surface layer of the
crystal dissolve, and the crystallinity (long- range order) is preserved in the center of the
solid. These observations are consistent with the visual observation of a dissolving
crystal.

a

b

c

Figure 12. (a) The 4 x 4 x 4 crystal of APAP after equilibration (at 0 ns) viewed down crystallographic c axis. (b) Image taken at 3 ns.
(c) Image taken at 10 ns.
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Order of Molecule Dissolution
As expected, the molecules located on the surfaces of the crystal dissolve into the
solution first. To gain understanding in the molecules dissolved and their relationship
with the crystal, we used the VMD software to examine the order of release for the
molecules. The hypothesis is that a predictable pattern exists between the location of the
APAP molecules and their order of release.
In Figure 13, a series of images were captured at different times of dissolution (0.3–
10 ns). A clear trend was observed when the dissolved APAP molecules were correlated
with the groups that reflect their original locations on the crystal. The preference of initial
release is more toward the corners of the crystal, especially along the two more acute
corners (sharper corners). The secondary release is from the edges, and finally the flat
surfaces release APAP last. This indicates that the molecules are not leaving the crystal
surfaces randomly but in an organized fashion.
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Figure 13. Demonstration of the molecule release profile with time. Undissolved APAPs
are shown in line style. Dissolved APAPs are shown in bulky VDW style. From left to
right and from top to bottom, 0, 0.3, 0.6, 0.9, 1.8, 2.7, 4.5, 7.5 and 10 ns. All are viewed
down crystallographic b axis.
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Interaction Energy Calculation among
APAP Molecules
To determine the theoretical basis of the observed position-dependent release, total
interaction energies were calculated between each individual of the 256 APAP molecules
and their immediate surrounding APAP molecules within 4 Å over the 10 ns time frame.
The total interaction energies are a sum of the van der Waals and electrostatic forces. To
illustrate the calculated results, the following APAPs were chosen to represent different
initial positions: (1) two molecules that are located in the center of the crystal and have
never left their original locations during the 10 ns simulation; (2) a molecule located on
(010) layer 2 that has never dissolved; (3) a molecule located on (100) layer 1 that was
not dissolved within 3 ns but eventually left at 8.1 ns, and (4) two APAPs that dissolved
within 3 ns including one released at 1.2 ns in the corner group and another released at
1.9 ns in the edge group. It was expected that at time zero the APAP molecule being
evaluated should interact through electrostatic and van de Waals forces with its
surrounding APAPs. When an APAP is dissolving into water, such interactions should
decrease significantly or completely since the dissolved APAP is no longer in contact
with the neighboring APAP molecules that are initially surrounding it. At the same time,
the interaction with the solvent molecules should increase.
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Figure 14. The change of total interaction energy as a function of time for selected APAP
molecules: solid blue line (▬▬▬): energy between APAP and its surrounding APAP
molecules; dotted pink line (– – – –): energy between APAP and all water molecules;
solid light blue line (▬▬▬▬▬▬): energy between APAP and all chloride ion [Cl]-1); solid
red line (▬▬▬▬▬▬): energy between APAP and all sodium ion [Na]+1). (a, b) two APAPs
located in the center of the crystal that have never been released. (c) an APAP located on
(010) layer 2 that has never been released. (d) an APAP on (100) layer 1 that released at
8.1 ns (later than 3 ns). (e, f) two APAP molecules released within 3 ns, one on corner
released at 1.2 ns and one on edge released at 1.9 ns.
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A series of plots in blue colored solid lines in Figure 14 depicts the calculated total
interaction energy with surrounding APAPs over the course of 10 ns for the preceding list
of APAP molecules. The data demonstrate the outcome as what has been predicted. In
every plot, the initial total energy is always negative, and the energy level fluctuates from
time 0 to 10 ns. However, there are profound differences in the interaction energy profiles
among these different APAP molecules. Molecules that are located in the center of the
crystal exhibited the highest interaction energies (the most negative) with the surrounding
APAP molecules. The total energy exceeded –250 kJ/mole initially and remained with
little or no change throughout since their local environments do not change during the
course of simulation. The molecule in the (010) second layer also never escaped and
started with the total energy close to –200 kJ/mole, which gradually changed to about –
125 kJ/mole at the end of 10 ns. However the interaction energy of this molecule never
went to 0, suggesting that it maintained strong enough interaction with its neighboring
APAP molecules to prevent it from leaving the crystal surface. The APAP molecule
located on layer 1 of (100) has an initial energy of about –130 kJ/mole (much less than
those of those two preceding cases), but the energy drifts downward to –10 kJ/mole at 1.5
ns, and at 8.1 ns, the energy takes a deep dive down to 0 kJ/mole. This is precisely what
was determined by the visual observation using VMD. As illustrated in Figure 15, this
(100) Layer 1 molecule was initially wrapped inside a group of adjacent APAPs. At 1.5
ns, the molecule moved half way out of the pocket and lost contact with most of the
surrounding APAPs, which is consistent with the interaction energy dropping to –10
kJ/mole. At 8.1 ns, it dissolves and no longer associated with any of the APAPs initially
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surrounding it, resulting in the interaction energy decreasing to 0. The earlier released
APAP molecules, in the corner group and in the edge group have smaller initial
interaction energy (–64 to –70 kJ/mole) and released earlier at 1.2 and 1.9 ns,
respectively. In all cases, the timing when the total energy changes to zero always
corresponds to the time of molecule dissolving into water phase.
The total interaction energies of –250 kJ/mole for the APAP located in the center of
the crystal would seem to be too large a number from lattice energy perspective (ΔHf of
APAP Form I is 28.1 ± 2.2 kJ/mole104). The reason is that for the entire crystal, this
calculation would multiply count interactions. Thus, if an APAP molecule in the center of
the crystal is surrounded by 10 other APAP molecules then the actual lattice energy
would be 1/10th of the value we calculated. The range of interaction energy values
reported by us is in line with other studies.64
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Figure 15. Visual depiction of events occurring at sudden alterations in APAP/APAP
interaction curve of the molecule on (100) layer 1 (panel d in Figure 14). From left to
right, (1) the molecule surround by nine APAP molecules at t = 0 ns; (2) status of the
molecule at t =1.5 ns (it only has contact with two of the nine surrounding APAPs; (3)
position at t = 8.1 ns (it dissolved, losing contact with all APAPs initially surrounding it
with interaction energies decreasing to zero).
Interaction Energies between APAP and
NaCl Molecules
The MD simulation was conducted in the presence of 0.15 M NaCl. The effect of
NaCl on the solubility of APAP was evaluated also through the perspective of interaction
energies. The total interaction energies for the same set of selected APAP molecules in
Figure 5 with surrounding Na+ and Cl- within 4 Å were calculated in the course of 10 ns
simulation. The APAP molecules in the center of the crystal (Figure 5a,b) and in the
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second surface layer (Figure 5c) have little or no contact with the dissolution medium;
therefore, the interaction energies with Na+ or Cl- are zero or almost zero. The surface
layer APAP molecules (Figure 5d,e,f), on the other hand, were shown to have interactions
with Na+ or Cl-, especially when the molecules are released into the water phase. The
interaction with Na+ or Cl- is sporadic and weak in general when compared with the
strength of APAP–water interactions. Only rarely the APAP/Na+ interaction became as
strong as the APAP–water interactions.
Interaction Energies between APAP and
Water Molecules
During the dissolution process, drug molecules interact with water. One way of
investigating this interaction is to look at the changes in van der Waals and electrostatic
energies between APAP and water molecules over the 10 ns period. The interaction
energies between a specific APAP molecule (same groups of APAPs as shown above)
and the waters were calculated at 0.03 ns intervals and overlaid with the APAP/APAPs
interaction curves in Figure 14. It is clear that the water interaction is complementary to
the APAP intermolecular interactions. The loss in interaction between APAPs was gained
back from their interaction with water. However, these APAP/water interaction energy
profiles are somewhat different from those of APAP/APAPs in that they fluctuate
significantly in amplitude after the APAP molecules dissolve. In order to understand this,
we calculated the numbers of water molecules within 4 Å of the designated APAP at 0.03
ns resolution. The resultant water number vs time profiles were compared with values of
APAP/water and APAP/NaCl interaction energies in Figure 16. It is interesting to note
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that the variation in number of waters is completely superimposable with the fluctuation
in APAP/water interaction energies, indicating that the primary cause for the big swings
in APAP/water interaction energy is the change in numbers of water molecules
interacting with the APAP molecules (solvation number). A minor contribution lies in the
interaction with NaCl; a few downward spikes (significant decreases) in the APAP/water
interaction energies can be attributed to the increases in the APAP/NaCl interactions.
Over the entire time, the numbers of waters that are interacting with APAPs vary
constantly and dramatically (numbers spanning from 9 to 37 in the case of the APAP on
the corner). These results painted a realistic picture of how a molecule interacts with
water in solution. The solvation number, if obtained experimentally, will be an average of
these dynamics. The MD simulation is able to clearly capture this dynamic image.
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Figure 16. Correlation of APAP–water interaction level fluctuation with the number of
surrounding water molecules and the APAP–NaCl interaction. The first Y-axis on the left
is the change of total interaction energy as a function of time for selected APAP
molecules. Dotted pink line (– – – –): between APAP and all water molecules; Solid light
blue line (▬▬▬▬▬▬): between APAP and all chloride ion [Cl]-1); Solid red line
(▬▬▬▬▬▬): between APAP and all sodium ion [Na]+1). The second Y-axis on the
right is the number of water molecules in the adjacent of the APAP molecule within 4 Å.
Solid dark blue line (▬▬▬▬▬▬) is the change in number of water molecules over
time. (a) an APAP on (100) Layer 1 that released at 8.1 ns (later than 3 ns). (b, c) two
APAP molecules released within 3 ns, one on corner released at 1.2 ns, and one on edge
group released at 1.9 ns.
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Group Average Interaction Energies at Time 0
The initial van der Waals and electrostatic energies among the different groups of
APAP molecules were compared to further identify general relationships. This
calculation accounted for average interaction energy per APAP residue obtained from the
whole group at 0 ns. Both APAP/APAP and APAP/Water interactions for the seven
groups were calculated (Figure 17). The corner group on average possesses the smallest
interaction energy with their surrounding APAP molecules, followed by increasing
energy order of edge group, (001) layer 1, (010) layer 1, (100) layer 1, and (001)/(010)
layer 2 (Figure 17a). When the interaction energy with water molecules is considered
(Figure 17b), the rank order is exactly reversed, with the corner group taking the lead
followed by edge group, (001) layer 1, (010) layer 1, (100) layer 1, and (001)/(010) layer
2. This comparison indicates there should be differences in dissolution rate among the
different groups. Figure 18 correlates the percentage of molecules released at different
times (3, 5 and 10 ns) with the differences in interaction energies. Since the interaction
energy among the drug molecules would deter dissolution, while the interaction energy
between the drug and water molecules would favor the dissolution, the difference
between these two forces (total interaction energy of APAP with water minus that of
APAP with APAP) was plotted along the x-axis. The percent of release was calculated by
taking the ratio of released molecules in the specific group over the total APAP
molecules in the same group and plotted on the y-axis. There is a clear trend with a rank
order consistent with the preferential release profile among different groups at all three
time points (Figure 18). These data demonstrate that a strong correlation exists between
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the initial energy level and the extent of molecule release. The release rate follows the
order of corner group, edge group, (001) layer 1, (010) layer 1, and (100) layer 1.
Figure 17 also shows the different landscapes of van der Waals energy vs
electrostatic energy among the different groups. The van der Waals energy comprises a
significant portion in the total energies in groups of APAP/APAP interaction, while its
role in the APAP/water interaction seems less important than the more dominant
electrostatic forces. In the APAP/APAP interaction, electrostatic energy varies greatly
among different groups, while the interaction contribution by van der Waals interactions
is relatively more uniform.
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Figure 17. Initial interaction energies expressed as an average for each group. (a) Energy
between APAP and its surrounding APAPs; (dark green bar) van der Waals, (light green
bars) electrostatic. (b) Energy between APAP and surrounding water molecules; (dark
blue bars) van der Waals, (light blue bars) electrostatic.
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middle graph, t = 5 ns; bottom graph, t = 10 ns.
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Physical Observation of APAP Crystal Dissolution
The molecular dynamic simulation of a nanoscale dissolution showed that the first
groups of molecules to leave the crystal surface are located on the corners and along the
edges. To test whether this phenomenon would occur during macroscale crystal
dissolution, a visual dissolution was performed while observing a large size APAP crystal
under a microscope. The visual dissolution results are captured in Figure 19. In the
beginning, the crystal has well-defined shape and sharp edges (Figure 19a). However, as
dissolution progressed, the corner quickly changed shape, and the edges became blurred
and dull (Figure 19b). If the molecules had left all surfaces at a same rate without any
preferences, the original shape of the crystal should have remained. Therefore,
experimental observations support the simulation results.
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a

b

Figure 19. Visual observation of dissolution of an APAP crystal in 0.15 M sodium
chloride solution under a polarized light microscope at 4× magnifications. (a) Initial
image before adding dissolution medium; (b) Seven min after adding dissolution
medium.
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Discussion
Molecular Release in Dissolution Process and
Interaction Energies
The MD simulation clearly showed how each molecule leaves the crystal surface to
enter the water phase. The dissolution process is far from simply a random action. The
sequence at which the molecules leave the crystal surface follows a defined pattern: the
molecules located at corners, especially at the sharper corners, follow a trend of
dissolving earlier, followed by those on edges, and very few from the center of flat
surfaces have dissolved (Figure 13). According to Wang and Flanagan,6 neighboring
molecules on a solid (either crystalline or amorphous) are closely associated with each
other through intermolecular forces. Dissolution involves the breaking of these existing
intermolecular interactions, and then the formation of new interactions with dissolution
medium (0.15 M NaCl in our simulation experiment). In the present study, the interaction
energies among the molecules located in different places of the crystal were calculated as
the sum of the electrostatic forces and van der Waals energies. The APAP molecules
located on corners and edges are relatively loosely associated with their surrounding
APAP molecules (Figure 17a) indicated by total interaction energies (–60 to –106
kJ/mole) at time zero being smaller than the total energies of their surface bound
counterparts (in the vicinity of –130 to –170 kJ/mole) and even smaller than those in the
second layers (~ –200 kJ/mole) or buried inside the crystals (total initial energies around 250 kJ/mole) in Figure 14a,b. The larger the bound energy the molecule possesses, the
more difficult it is for it to release into the water. Once the molecule is released into the
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water phase, the total interaction energy between APAP and surrounding APAP
molecules immediately disappears (Figure 14).
Sometimes, the total interaction energy vs time profile for a single APAP molecule
(Figure 14b,d) undergoes changes not related to dissolution of the molecule, which were
found by visual inspection with VMD to be directly linked to the physical movement of
the molecule. For example in Figure 15, both sudden decreases at 1.5 and 8.1 ns in
Figure 14d are caused by the loss of contact with its surrounding molecules. In another
example, the change at ~1.5 ns to the molecule located in the center of the crystal
(Figure 14b) is due to the dissolution of a molecule that initially binds to this center
molecule, resulting in some exposure to water (graphical illustration not shown). By
plotting the total interaction energy of APAP molecules with their surrounding APAP
molecules vs time (Figure 14), one can determine when a molecule dissolves (interaction
energy changing to 0) or has changed in its relationship with adjacent molecules. This has
been demonstrated in all 256 APAPs (data not shown for all). These results indicate that
the energy computational method is a powerful tool in analyzing the dissolution
simulation data.
Sodium chloride at 0.15 M to mimic the ionic strength of biological fluid was
present in the solubility simulation of APAP. Electrolytes such as sodium chloride are
known to potentially affect solubility. They can attract water molecules and reduce the
density of the aqueous environment adjacent to the solute molecules, causing lower
solubility (salting out effect). They may also interact directly with the solute molecules,
resulting in higher solubility (salting in effect). The total interaction energies between

+

–
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APAP and Na and Cl for select APAPs are plotted in Figure 5. As expected, only the
surface layer APAP molecules (Figure 5d,e,f) were shown to have interactions with Na+
or Cl–. Compared to APAP/water interactions, such interactions take place sporadically
with much smaller energy in general. Most of the time, the interaction energies are in the
range of –50 to –100 kJ/mole which are much less than the strength of APAP–water
interactions (on average at –250 kJ/mole). Only very occasionally and for very short
durations, the APAP/Na+ (ion-dipole) interactions reached the level of APAP–water
interactions. The reason for the relatively much smaller overall interaction energy is the
overwhelmingly larger number of waters vs NaCl molecules present in the system; for
every NaCl molecule, there are 370 water molecules. As a result, the effect of 0.15 M
NaCl on the solubilization of APAP in water is minimal. This is consistent with the
measured solubility values of APAP in the presence and in the absence of NaCl, which
are hardly distinguishable (20.0 ± 0.2 in our study vs 21.03 ± 0.13 mg/mL103).
The water molecules play a significant role in “dragging” the drug molecules into
the aqueous phase, which is the second step in the dissolution process. This can be
demonstrated by calculating the interaction energies between APAP molecules and the
water molecules. As shown in Figure 14, water molecules do establish new interactions
with those APAP molecules that are dissolved, and they have fewer interactions with
those APAP molecules that are not dissolved. The group average initial interaction
energies with water (Figure 17b) followed the opposite trend as those between APAP
molecules (Figure 17a). The stronger interaction with water positively contributed to
dissolution.
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Figure 14 and Figure 17 revealed that the dissolution pattern observed at the
molecular level (Figure 13) is governed by the interplay between the interaction energies
formed among the APAP molecules and between the APAP and water molecules.
Figure 18 demonstrates that the net difference between these two types of interaction
energies is the underlying cause for the differences in dissolution rate from different areas
of the crystal. Dissolution rate has been long established to be directly correlated to
solubility,4 a thermodynamic property. The dissolution process can be viewed as a
pseudochemical reaction, which is governed by thermodynamics. The Gibbs free energy,
ΔG, is the balance between enthalpy, ΔH, and entropy, ΔS, at given temperature T (ΔG =
ΔH – TΔS). ΔG needs to be negative in order for dissolution to occur. Since dissolution
produces more randomness of molecules in the entire system (including solid and
solution states), the ΔS term is generally positive. Thus, net enthalpy is the term to
determine whether or not ΔG will become negative.6 Further, the contribution of entropy
to dissolution is the same regardless the location of molecules on the crystal. Therefore,
the differences in dissolution rates are determined by the interaction energy based on the
location of the molecules. When the net interaction energy difference is negative
(interaction of APAP/water overwhelms that of APAP/APAP), dissolution of APAP into
water becomes favorable. This can explain why the dissolution in the corner group (with
net interaction of –89 kJ/mole) and the edge group (with net interaction energy of –
24 kJ/mole) is facile, and why the release percentage of the corner is higher than the edge
at early stages. In the surface layers of (100), (010) and (001), the APAP/APAP
intermolecular binding energy exceeded that of APAP/water. In this case, the molecules
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would favor staying on the crystal surface until the other term, ΔS, overcomes the
enthalpy barrier. This explains the very slow initial dissolution of the surface groups.
Among the surface groups, however, differences also exist. The (100) layer 1 started with
significantly higher water interaction (–108 kJ/mole) than the (010) layer 1 and (001)
(both at –72 kJ/mole) owing to the out-facing hydrophilic phenol moiety that presumably
facilitates the interaction with water molecules. As a result, this group as a whole is able
to dissolve much faster than the other two surface groups. The (010) and (001) crystal
faces which are not as hydrophilic have similar level of interactions with water
(Figure 17b), and consequently the initial dissolution rate is at a similar level too.
Eventually the dissolution of the (010) surface moved ahead of the (100) surface (Figure
8, bottom panel) because (010) surface is smaller than (100) in the 4 x 4 x 4 crystal and
closer to the edges and corners. Overall, the correlation is evident: with the decrease of
net interaction differences, the extent of dissolution from the fastest to the slowest
follows the rank order of corner group > edge group > (100) layer 1 > (010) layer 1 >
(001) layer 1 (Figure 18). Explained physically, corners have larger surfaces accessible to
water, resulting in more interactions with more water molecules. The same physical
argument can explain why edges have higher interaction with water than the flat surfaces.
We have discussed above the total interaction energies that have profoundly
influenced the rate of dissolution. The total interaction energies originate from two types
of forces: electrostatic (charge–charge, ion–dipole and hydrogen bonds) and van der
Waals (dipole-dipole, dipole–induced–dipole and dispersion forces). Various electrostatic
interactions are specific and directional. H-bonding has been viewed as the most
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important force to hold together organic solid crystals.
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H-bonding is also responsible

for solubility behavior of polar molecules such as drugs in solvents especially polar
solvents (e.g. water).106 Van der Waals interactions are nonspecific attraction forces and
proportional to radius–6 which fall off rapidly with increase of intermolecular distance.107
In the literature, the importance of van der Waals forces in the crystal lattice and
solubilization has not been emphasized to the degree that the H-bond has been. In
Figure 17a, we plotted the group average APAP intermolecular interaction energies
divided into electrostatic and van der Waals contributions. These plots revealed that Hbonding is an important force but not the only important force. Van der Waals comprises
a significant percent of the total interaction energy in all seven groups. Its contribution in
the corner and edge groups is almost at 50%. Similar plots were made to describe the
APAP/water interactions at the crystal/water interface (Figure 17b), in which the
electrostatic force is shown to be a much more dominating factor because water has an
exceptional capability to form H-bonds. Yet the portion of van der Waals contribution is
still not negligible. The strong correlation between percent of release and net interaction
energy shown in Figure 18 would have been lost if the van der Waals interactions were
excluded from consideration. The data in Figure 17 have demonstrated the significance of
both H-bond and van der Waals in lattice energy and in energetics of crystal dissolution.
Since both the electrostatic and van der Waals energies will depend on the structure of
the molecule, the relative importance of these two factors would vary for different
compounds.
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The distribution of van der Waals and electrostatic energy in two crystal surfaces,
(100) and (010) (Figure 17), warrants more discussion. These two groups of surface
molecules are packed similarly (Figure 11) so the van der Waals force is almost identical.
What is intriguing is the much larger electrostatic interaction energy of the (010) face
compared with that of (100) face. The answer was found after examining the H-bond
motifs on (100) and (010) faces. Each APAP on the (100) layer 1 forms two H-bonds:
O=C–N–H (1st layer) → O–H–Phe (2nd layer) and Phe–O–H (2nd layer) → O=C–N–H (1st
layer), while each APAP on (010) layer 1 is bound by three H-bonds to two APAPs in the
second layer: Phe–O–H (1st layer) → NH–C=O (molecule no. 1 in 2nd layer), Phe–O–H
(molecule no. 2 in 2nd layer) → O=C–NH– (1st layer) and O=C–NH (1st layer) → O–H–
Phe (molecule no. 2 in 2nd layer). Therefore, the (010) surface is associated with higher
electrostatic energy and should be more stable than the (100) surface just as demonstrated
in Figure 18.
The surface correlated dissolution indicates that different morphologies of the
crystals should exhibit different dissolution rates. Earlier theoretical assessment of shape
factor in dissolution rate suggested minimal influence,74 however, later reported
experimental evidence indicated otherwise. In a dissolution study of five single crystals,71
the shape factor changed significantly after 50% dissolution, which points to preferential
dissolution of different faces. In another theoretical study, the flux of aspirin from crystal
phase (100) is approximately 6 times faster than that from phase (001), which is
correlated with reported variations in the dissolution behavior of commercial aspirin
products.108 In one more report, single crystal dissolution was studied on APAP crystals

and different dissolution rates from phase (001) and (110) were found.
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Chow and

Grant conducted extensive studies on the physical factors (such as shape) affecting the
dissolution rate of APAP crystals.110 They found that the aspect ratio played a significant
role in the intrinsic dissolution rate of APAP, and an empirical equation can be
established to correlate the intrinsic dissolution rate with aspect ratio and other physical
factors such as incorporated impurity levels. In their empirical equation, the intrinsic
dissolution rate is exponentially proportional to the aspect ratio, l/w (length/width) [ln
(rate) = constant × ln l/w]. The aspect ratio affects the morphology and consequently the
amount of material in edges. Assume two rectangular crystals have the same solid
volume of 1000 nm3. Crystal no. 1 is a cube with l = 10 nm, and w = 10 nm, so the total
length of edges will be 120 nm (four times 10 nm times three). Crystal no. 2 is a needle
with l = 100 nm, and w = 1 nm, which will result in a total length in edges of 444 nm,
almost 4-fold of the edges as in a cubic crystal. Therefore, increasing l/w ratio results in
more abundance of edges. In a follow-up study,111 Chan and Grant confirmed that crystal
habit is the major factor that determines the intrinsic dissolution rate of acetaminophen
crystals. Their experimental findings are consistent with what we have observed here in
our MD simulation. The MD simulation demonstrates that morphology is expected to
affect the dissolution rate due to different interaction energies intrinsically presented in
different surfaces of APAP crystals. Since corners and edges have fewer APAP–APAP
interactions and more APAP–water interactions, increasing the aspect ratio would boost
the dissolution rate.
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Solubility and Dissolution Rate
vs Particle Size
Upon completion of the simulation, one question immediately became obvious:
why is the dissolution so fast? Within 10 ns, the APAP concentration in the water box
reached about 40% of the solubility. The APAP crystal built for dissolution simulation
consists of 256 molecules with 5120 atoms. The volume of the crystal is 5.0 × 103 Å3
which translates to a diameter of about 4.6 nm (radius of 2.3 nm) for a spherical crystal.
Based on classical nucleation theory, a crystalline lattice structure will be stabilized when
it reaches the critical radius, rc. Particles smaller than rc will dissolve or evaporate.112 The
size of a critical nucleus typically falls in the range of 100–1000 atoms,113 which is far
exceeded by the 5120 atoms in the APAP 4 x 4 x 4 crystal lattice. The fact that the 4 x 4
x 4 nanocrystal did not dissolve after being subjected to the initial equilibration step
(Figure 12a) further confirmed its stability. Hence, using this 4.6 nm crystal to simulate
crystal dissolution is proper and justified.
It is known that the saturation solubility can be increased when the particle size is
decreased to smaller than 100 nm and the extent of solubility increase can be calculated
by the Thomas–Freundlich equation.114

ln

Cs ,r 2Vm

Cs , rRT

(Equation 1)

Where Cs,r/Cs,∞ is the ratio of solubilities when particle size is decreased from a large
particle (∞) to a smaller one with radius of r, γ is the interfacial tension, Vm is the molar
volume of the particle (the molecular weight divided by the density), R is the gas
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constant, and T is the absolute temperature. With APAP’s molecular weight of
151.16 g/mol, density of 1.2 g/cm3, the interfacial free energy of 30 mJ/m2 at 310 K
(37 °C),114 the solubility of a r = 2.3 nm APAP crystal is calculated to be 3.6 times of the
solubility of a macro crystal.
It is also known that the dissolution rate of the nanosized crystal will increase over
that of a large particle. The dissolution rate constant, k, can be calculated by Higuchi and
Hiestand equation (also known as two-thirds-root expression), which was derived for
diffusion layer based dissolution of very small particles:6
 4N 
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Where ρ is the density of the particle, N is the number of particles, D is the diffusion
coefficient, and Cs is the solubility.
The dissolution rate constant of a small particle, kS, vs the dissolution rate constant
of a large particle, kL, can be calculated by taking the ratio of kS/kL from eq 2. When
comparing kS with kL in this calculation, it is assumed that the same amount of drug
sample was added into the dissolution medium so that the weight portion from the ρ term
can be canceled out. It is also assumed that diffusivity, D, between the large and small
particles is similar. After simplification of eq 2, the ratio of kS/kL is expressed in the
following equation:

kS Csol , S

k L Csol , L

r 
  L 
 rS 

2

(Equation 3)
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where Csol,S is the solubility of the small particle, Csol,L is the solubility of the large
particle, rL is the radius of a large particle and rS is the radius of a small particle. Notice
that the solubility of the nanocrystal of APAP is 3.6 times that of the large particle from
the Thomas–Freundlich equation. Assuming a large particle has a particle size of 10 µm
(a commonly used particle size for drugs), the dissolution ratio, ks/kL, is 3.6 ×
(10000 nm/ 2.3 nm)2 = 6.8 × 107. Putting this value in practical perspective, if the large
particle (10 µm) takes 20 min to reach 40% saturation, the 2.3 nm nanocrystal will take
17.6 µs (20 × 60 s/6.8×107) to reach the same level of saturation. This 17.6 µs dissolution
time is still 3 orders of magnitude longer than the 10 ns simulation time. Thus, in our MD
simulation of the dissolution, the crystal takes a shorter time to dissolve than it would in a
conventional experiment. The reason is not clear; however, it is consistent with the other
published MD simulations. For example, Parker and co-workers48 simulated dissolving a
small surface layer of a calcium carbonate crystal over 200 ps (0.2 ns). In another paper
by Bhargava and co-workers,115 the initial aggregation of surface active ionic liquid was
simulated within 4 ns although the complete aggregation process takes microseconds to
milliseconds. In a recently published work by Yani and co-workers,64 the production run
on the interaction between polymer and salbutamol sulfate crystal utilized simulation
time less than 1 ns. Apparently, the time scale differences will not discount the important
findings discovered by MS simulations.
Corner and Edge Effect
A perfect crystal surface is more difficult to dissolve. Indeed there are no molecules
from the center of the perfect APAP 4 x 4 x 4 crystal surfaces to dissolve initially
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(Figure 13). In our simulation, the first three dissolved molecules are all located at
corners, followed by several on edges. The strong trend where the APAP molecules at the
corners and edges, especially at the corners, dissolved before other molecules persisted
all the way to the end of the 10 ns in this simulation. The same was observed in another
two MD simulations we have completed earlier using different sizes of crystal and water
box (detailed data not shown). The first simulation was done on a much smaller crystal (3
x 3 x 3 crystal lattice, 27 APAP molecules) in a 20 Å water box. The second one was on
the same large size crystal (4 x 4 x 4 lattice, 256 APAPs) but in a smaller 25 Å water box
containing about 1/5 of the water molecules presented in the 40 Å water box. Both of
these additional MD simulations also show without doubt that molecules released first
from corners and edges. We have also conducted a real dissolution experiment of a large
crystal, millimeter size (Figure 19). The results confirmed that corners and edges
disappear first, which rendered dull the edges of the crystal. Therefore, the corners and
edges serve as the initial sites for dissolution in perfect single crystals.
The corner and edge effect has an underlying theoretical basis. In a reported study
using bond valence calculations, Schindler and Mutter116 explained that the cluster of
crystals on the edge of a mineral sheet would develop activated sites first and dissolve
into aqueous solution. In our MD simulation, the order of molecule dissolution is a result
of the interplay between the interaction energies formed among the APAP molecules and
between the APAP molecules and water with the corner and edge groups clearly
differentiating themselves from the surface groups (Figure 18). This interaction energy
calculation provides strong evidence that corners and edges should dissolve first in a
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perfect crystal. Once a molecule breaks free from the corners or edges, new corners and
edges will be created instantaneously, forming new sites for the next wave of molecules
to dissolve. This domino wave will gradually reach the molecules originally on surfaces,
where the relatively weakly associated surface molecules will dissolve prior to the more
tightly bound surface molecules. Such a dynamic dissolution process will proceed until
the whole crystal disappears or until saturation is reached. In practical crystallization
processes, a variety of surface imperfections can be produced as a result of mechanical or
thermal stress or irregular growth.112 In this case, besides corners and edges, the
imperfect surface spots can also take the lead in dissolution, creating new corners and
edges on the way.
It was widely accepted that the dissolution rate correlates with the total particle
surface area. Now based on our findings, the initial dissolution rate probably is more
correlated with the number, the length and the shape of the corners and edges in the
particles. The knowledge of the corner and edge effect allows us to better understand
particle size reduction, a very useful technology to increase dissolution rate of poorly
water–soluble drugs. Common knowledge holds that particle reduction technology works
by creating more surface area. Based on our study, the important underlying mechanism
is, at least in part, the creation of proportionately more corners, edges, and other defects
when the particles are turned into smaller ones. The advantage of smaller particles lies in
the superior accessibility to dissolution media; the molecules in the center of the smaller
particles need not wait as long as those in the center of the bigger ones to “see the light at
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the end of the tunnel”. The presence of larger numbers of the faster dissolving defect
spots in milled tiny particles essentially accelerates the accessibility to dissolution media.
Conclusions
We have presented here molecular dynamic simulation of acetaminophen Form I
dissolving into an isotonic aqueous medium at 37 °C. The results clearly demonstrate that
dissolution from a crystal is not a random process. It is strongly governed by the
electrostatic and van der Waals interaction energies among the solute molecules and
solute–solvent molecules, with a non-negligible contribution from van der Waals forces.
The distribution of the interaction energies has a unique geometric entity: the molecules
located on corners and edges of the rectangular parallelepiped crystal are not as tightly
bound to their surrounding neighbors as those located in other surfaces. Therefore they
are less restricted and tend to dissolve more readily. Furthermore, the simulation results
were confirmed by the dissolution experiment. These results prompted us to rethink the
fundamentals of particle size reduction in enhancing dissolution rate. The presence of
larger numbers of the faster dissolving corners, edges, and other defect spots produced by
milling accelerated the accessibility of small particles to dissolution media. This is
different from the conventional view of attributing to the flat surface area, although the
accompanying consequences, the increases in dissolution rate, are the same. The findings
presented here are very relevant in the context of particles size reduction and delivery of
poorly soluble compounds.
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CHAPTER FOUR
UNIQUE MECHANISM OF FACILE POLYMORPHIC CONVERSION
OF ACETAMINOPHEN IN AQUEOUS MEDIUM
Abstract
For acetaminophen (APAP), the fast conversion from the metastable orthorhombic
crystal Form II to the stable monoclinic Form I in solution has been observed ever since
the Form II was discovered decades ago. Since the conversion taken place when the solid
comes in contact with solutions, it has been believed that the process followed a solutionmediated phase transformation. However, little has been understood as to exactly which
factors are contributing to the fast kinetics. The present study was undertaken to examine
both thermodynamic and kinetic driving forces that lead to this facile polymorphic
conversion. The thermodynamic solubility of Form II in 0.15 M aqueous NaCl solution at
37 °C was obtained for the first time using a new solubility method with the aid of low
level (0.02%) of poly(vinyl pyrrolidone) (PVP) to inhibit crystallization of Form I. The
solubility ratio of Form II over Form I, which represents the thermodynamic driving force
for the conversion, is only 1.27 ± 0.04. Further experiments to monitor crystallization at
supersaturation levels at or even much greater than Form II solubility did not result in any
crystallization in ten days at 37 °C. Essentially, Form II is not able to generate
sufficiently high supersaturation to nucleate Form I through dissolution at 37 °C. In other
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words, the fast conversion is not possible through the solution-mediated phase
transformation. To identify other possibilities, molecular dynamics (MD) simulations
were conducted that investigated the molecular level dissolution behavior and the solid
state differences between the two crystalline forms. It was found that Form II behaves
very differently from Form I when exposed to solution. Form II showed much higher rate
of H-bond breaking, causing the accumulation of large numbers of APAP molecules on
the crystal surface. This thick disordered molecular layer on Form II surface provides
high local acetaminophen concentration for fast Form I crystallization. This was further
supported by the rapid surface recrystallization from a Form II crystal in solution
monitored under polarized light microscopy and by powder X-ray diffraction. Therefore,
the hydrated surface layer is the “catalyst” for the facile phase conversion. This new
mechanism, termed as SurFPT (surface facilitated phase transformation), could be much
more powerful in promoting polymorphic transformation in solutions than the wellknown solution-mediated phase transformation.

Key words: acetaminophen, molecular dynamics simulation, dissolution, metastable
form, solubility, orthorhombic, monoclinic, crystallization inhibition, polymorphic
transformation, and surface facilitated phase transformation.
Introduction
Polymorphic transition has been extensively studied in the pharmaceutical field due to its
significant impact on manufacturing and in vivo performance of pharmaceutical dosage
forms.17,117-119 A metastable solid form is energetically unfavorable and can convert to the
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thermodynamically stable form either through solution-mediated transformation in
solution or solid-solid transition over-time.17,120
Acetaminophen, a widely used analgesic and fever reducing medicine, has multiple
crystal forms. Among them, monoclinic Form I and orthorhombic Form II are the most
widely studied.121-126 Form I and Form II are monotropically related, Form I being more
stable127 and used commercially. Form I is difficult to compress into tablets. Thus, a more
costly wet granulation process needs to be performed prior to tableting.128 The dry blend
of orthorhombic Form II can be compressed directly to reduce manufacturing cost.124,128
Unfortunately, efforts to produce Form II on an industrial scale have proved unfruitful
because of the facile conversion to Form I in crystallization solvents.129 In aqueous
solutions, Form II also converted quickly to Form I130 which is why accurate Form II
solubility and dissolution data are missing from the literature for such a well-known drug
and polymorphic system. Even a large single crystal of Form II gradually recrystallized
into Form I at ambient temperature due to the inclusion of a small amount of water.131
Since the conversion occurs in the presence of solution, it was assumed that the solutionmediated polymorphic transformation is the mechanism responsible for such a
conversion.121,125,132 However, the details of the transformation have not been understood,
and the reasons for such fast conversion are mostly unknown. In particular, the following
important questions have not been addressed.
1. What is the thermodynamic driving force for the Form II to Form I
transformation?
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2. Will Form II dissolution be able to generate the supersaturation level
necessary for Form I to nucleate?
3. Are there other pathways to create the required supersaturation?
4. Are there alternative mechanisms that can account for the faster conversion?
Our present work is directed toward elucidating the mechanism of APAP Form II to
Form I conversion in 0.15 M aqueous solution of NaCl (designated as solubility medium
hereafter) at 37 °C. First, solubility measurement of Form II in the solubility medium at
37 °C was done accurately for the first time using a new experimental procedure. This
answers the first question regarding thermodynamic driving force. Molecular dynamics
(MD) simulations were then conducted to elucidate the structures of the solid phases
during dissolution of both Form I and Form II. The energetics of the molecule association
in the residual solids was studied through hydrogen bonding, pair correlation functions
and interaction energy calculations, which provide molecular or even atomic level
analysis that is not possible for any existing experimental methodology. The findings
from MD simulation led us to propose a new solid-form conversion mechanism (surface
facilitated phase transformation, SurFPT). Further experimental evidence is consistent
with this new mechanism.
Experimental
Material
Acetaminophen anhydrous monoclinic polymorph (Form I) with high purity was
purchased from Sigma (SigmaUltra, lot 116K0124). Deionized, distilled water for
preparing all solutions was purified to 18.2 mΩ/cm resistivity by passing distilled water
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through a deionizer/charcoal filter (Milli Q academic model, Millipore Corp., Bedford,
MA). Poly(vinyl pyrrolidone) (PVP) grade K30 was from Spectrum (lot XM3057).
Sodium chloride and other solvents and reagents used met ACS Reagent specifications.
Powder X-ray Diffractometry (PXRD)
Powder X-ray diffraction patterns of the samples were obtained using an Ultima+™
diffractometer controlled by DMAX2000 software (Rigaku Corp., Tokyo, Japan). The Xray source was a copper filament X-ray tube operated at 50 kV and 40 mA. Calibration of
the goniometer was monitored using standards (Sodalite and Si) prior to use. Micro cover
slides (0.15 mm in thickness) with a thin layer of samples were top-loaded onto a zero
background holder, and were scanned from 2–40° 2θ at 2–3°/min in a non-spinning
mode. Data analysis was accomplished using Jade software (Version 6.5, Materials Data,
Inc., Livermore, CA).
Preparation of APAP Form I and Form II Crystals
Form I
Crystals of Form I of sufficient size were prepared by recrystallization from water
according to reported procedures.133 The recrystallized crystals were monoclinic Form I
by PXRD (data not shown). The crystals in a sealed bottle were stored in a desiccator at
ambient temperature until use.
Form II
Multiple solution crystallizations were attempted in order to obtain sufficient
amount of metastable Form II. In one method, crystallization was conducted from ethanol
at 0 °C with seeding of melt-quenched Form II and harvesting crystals at 15 min.125
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Many repetitions of this method resulted in Form II contaminated with Form I. Variations
to this method by harvesting crystals at 2.5 min, by adding polymers (PVP or HPMC) to
crystallization medium, by switching to a different solvent with lower APAP solubility
(i.e. ethyl acetate and acetonitrile), and by lowering temperature using dry ice, all resulted
in mixture of Form I and II in repeated experiments. Additionally, crystallization in the
presence of 10 mg/mL alginic acid sodium salt was conducted according to a published
method,134 but without success.
Pure metastable Form II used in the studies was crystallized from the melt of Form I
following a published method125 with some modifications. A thin layer (~10 mg) of Form
I powder was spread in the center of a micro cover glass (18 × 18 × 0.15 mm, no. 1,
VWR International, Pennsylvania, US), which was heated for ~3 seconds on a hot plate
set at 170 °C (above m.p. of 168.6 °C104). The clear melt on the cover glass was cooled
down to ambient temperature (~23 °C). Crystallization started at about 5 min. After 30–
60 min, the cover glass was stored flat in a sealed glass petri dish under ambient
conditions. The sample was allowed to age for at least two days. Right before use, each
cover glass was directly placed on an X-ray sample holder for PXRD analysis. Only
those confined to pure Form II according to PXRD were selected in solubility and surface
crystallization studies.
Solubility Measurement of Form I and Form II
Form II
The first step was to identify a polymer that can retard or inhibit the conversion of
Form II to Form I in solubility medium. PVP was selected based on its interaction with

APAP.
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The PXRD-confirmed pure Form II on the cover glass was topped with the

solubility medium in the absence and presence of 20 µg/mL PVP (0.002%). After 45 min
at ambient temperature, the liquid was removed by a filter paper, and the cover glasses
were brought for PXRD scan. The sample without PVP was found to contain Form I
peaks, while PVP was shown to effectively prohibited the formation of Form I (data not
shown). Therefore, 20 µg/mL PVP was added to the solubility medium in the solubility
measurement.
Equilibrium solubility of Form II was carried out at 37 °C in the solubility medium
containing 20 µg/mL PVP. A procedure very different from conventional shake flask
method was designed to enable this measurement. Solubility medium with PVP (150 µL)
was added to the cover glass to top the surface of the Form II crystal layer. The cover
glass, supported by an X-ray sample holder, was placed inside a container with a loose lid
(i.e. a 60 mm × 15 mm cell culture dish). The dish was then loaded into a large diameter
glass bottle (100 × 50 mm) and tightly sealed with a lid. Further, to prevent the loss of the
solubility medium through evaporation which might lead to inaccuracy of the solubility,
the water vapor pressure inside the glass bottle was maintained by including two beakers,
each holding 5 mL of solubility medium with 20 µg/mL PVP. Finally, the whole
assembly was equilibrated at 50 rpm in a horizontal shaker (Incubating Orbital Shaker,
VWR International, Pennsylvania, US) set at 37 °C. Sampling was made by taking out
the X-ray sample holder and inserting a pipette tip into the clear solution phase at
multiple time points of about 20, 40 and 60 hrs. The clear solution sample was diluted
with water in a volumetric flask and analyzed by a HPLC assay using a five-point
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external standard curve. After taking the last sample, the residual solid on the cover glass
was again scanned for PXRD patterns. A total of 11 replicates were tested. The solubility
values obtained from samples with final solid form remaining as pure Form II or mostly
Form II were averaged and reported as the solubility of Form II.
Form I
Equilibrium solubility was determined at 37 °C in the solubility medium in the
absence and presence of 20 µg/mL PVP (0.002%). Several crystals of recrystallized Form
I (total weight of ~35 mg) were weighed into a 4 mL glass vial and 0.5 mL of solubility
medium was added. The glass vials, in triplicate under each condition, were agitated in
the same way as the Form II samples on the horizontal shaker. Sampling and
concentration analysis were also performed following the same procedure used for Form
II. The average concentration of the saturated solutions was reported as the solubility at
37 °C.
Physical Stability of APAP Solutions Supersaturated
at Concentrations of Form II Solubility and Above
This experiment determined if Form I can crystallize in solutions when the APAP
concentration is at or greater than saturation solubility of Form II. Concentrations
selected to study were 25, 26, 27, 28, 29, 30, 32, 34, 35 and 45 mg/ mL in the solubility
medium, each in triplicate. These supersaturated solutions were prepared by heating
suspensions of APAP Form I in sealed 4 mL glass vials on a heating block initially at
50 °C and then briefly at 60–70 °C with shaking. The 45 mg/mL samples were further
heated at 80 °C for ~2 min. The clear solutions were quickly transferred to the orbital
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shaker set at 37 °C and 50 rpm (same conditions as used in the solubility study).
Crystallization was monitored visually up to 12 days.
Theoretical Methods
Building the Crystal
Virtual crystals of Form I and Form II were constructed using the unit cell as a
building block in Mercury software (Mercury 2.3, CCDC 2001-2009), following the
method previously published in MD simulation of APAP Form I.41 The two crystal
lattices were built to render the best match in terms of overall geometric shape. As
reported before,41 the monoclinic anhydrous Form I lattice repeated the unit cell four
times along all three axes. The resultant lattice is referred to as APAP I 4 x 4 x 4. The
orthorhombic anhydrous Form II lattice extended the unit cell at a, b, and c directions for
3, 3 and 4 times, respectively, producing the APAP II 3 x 3 x 4 crystal lattice. The single
crystal structure of Form II was taken from HXACAN136 available from the Cambridge
Structural Database (Cambridge, UK). More details of crystal lattice parameters of both
APAP polymorphs built for MD simulation are listed in Table 2.

Table 2. Comparison of the Built Crystal Lattices of APAP I 4 × 4 × 4 and APAP II 3 × 3 × 4

Unit cell dimension (Å)
Polymorph

Z
a

b

c

Form I,
monoclinic

12.93

9.40

7.10

4

Form II,
orthorhombic

11.81

17.16

7.39

8

Lattice
built

Crystal dimension
(Å)

no. of
molecules
in lattice

Crystal
surface area
(Å2)

Length of
edges (Å)

Crystal
size (nm)

a

b

c

4×4×4

51.72

37.60

28.40

256

8.67×103

1430.9

4.56

3×3×4

35.42

51.49

29.57

288

8.79×103

1426.0

4.69
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Preparing the Crystal for Simulation
The crystals constructed above were prepared using Visual Molecular Dynamics
software (VMD, version 1.9, March 2011).99 First, the structure file of the crystal was
built using the Automatic PSF Builder function from the input of the Mercury file and the
APAP topology file. The topology and atom types for the CHARMM2739 force field for
APAP were obtained by comparison with similar molecules already in the standard
topology file. Second, a water box was built to surround the crystal. The water box
(containing 0.15 M sodium chloride) extends 40 Å on each side of the crystals. The final
size of APAP I 4 x 4 x 4 in water box is 131.7 × 117.6 × 108.4 Å3 (equal to 1.51 × 10-18
milliliters, with 58622 TIP3 molecules), and that of APAP II 3 x 3 x 4 is 115.4 × 131.5 ×
109.6 Å3 (equal to 1.66 × 10-18 milliliters). The ratio of water molecules to NaCl
molecules in the system is 370 to 1.
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1a

1b

2a

2b

Figure 20. (1a) Unit cell of monoclinic Form I (dotted line indicating hydrogen bonds).
(1b) APAP I 4 x 4 x 4 crystal in the 131.7 × 117.6 × 108.4 Å3 water box. (2a) Unit cell of
orthorhombic Form II (dotted line indicating hydrogen bonds). (2b) APAP II 3 x 3 x 4
crystal in the 115.4 × 131.5 × 109.6 Å3 water box.
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MD Simulation
The computer code used for the MD simulations was the parallel, scalable MD
program NAMD version 2.5.100 Periodic boundary conditions were used. The cutoffs for
nonbonding (van der Waals and electrostatic) interactions were 12 Å. The switch distance
was 10 Å, and a 1.0 1–4 scaling factor was used. The crystal in the water box was first
subjected to energy minimization (6000 steps) followed by slow heating from 10 to
310 K over 30000 steps. The temperature and pressure of the system were equilibrated
for 10000 steps using a Langevin piston. The system was then allowed to equilibrate for
30000 steps at constant temperature (310 K) and pressure (1 atm) before production data
was accumulated. Production simulations (10 ns) were performed at constant volume and
temperature.
Analysis of MD Simulation Data
Calculation of Number of Molecules Dissolved vs Time
The number of APAP molecules out of the sphere of the original crystal lattice and
into the water box were tracked at 0.03 ns intervals for 10 ns simulations for both Form I
and Form II, using a script written for the VMD program (version 1.9).99 The data were
plotted using Microsoft Excel (Version 2010).
Calculation of Interaction Energies
Interaction energies were calculated as previously described41 using algorithms of
the van der Waals and electrostatic energies and the NAMD program.100 These
calculations were performed for APAP molecules located on corners and edges with their
surrounding APAP molecules or water molecules within 4 Å. The electrostatic
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interactions, including ion–dipole interactions and H-bonding, and van der Waals were
calculated using the partial atomic charges (CHARMM 27 potential function39). The sum
of electrostatic and van der Waals interaction energies is the total interaction energy
reported here.
Calculation of Hydrogen Bonds
The numbers of hydrogen bonds formed throughout a trajectory among APAP
molecules in both Form I and Form II were calculated by HBonds Plugin (version 12) in
VMD program (version 1.9).99 A hydrogen bond was counted between an atom with a
hydrogen bonded to it (the donor, D) and another atom (the acceptor, A) by defining that
the distance D-A is less than 3.4 Å and the angle D-H-A is less than 30 degrees. The
percentage of H-bond broken normalized to the initial H-bond numbers was constructed
for both Form I and Form II, and plotted against the time scale.
Calculation of Radial Distribution Function g(r)
The radial distribution function g(r) of APAP, also called pair correlation function,
over a given trajectory of Form I or Form II in the water box was computed by g(r) GUI
Plugin (version 1.2) in VMD program (version 1.9).99 An APAP molecule located in the
center of the crystal was the chosen origin. The spherical shell was defined as 50 Å from
the origin. The periodic boundary conditions were enabled during the calculation. The
calculated g(r) describes the variations in atomic density as a function of distance from
the origin to the coordinates of other APAP molecules within the defined spherical shell.
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Polymorphic Transformation Determined
by PLM and PXRD
Polarized light microscopy (PLM) was used to visualize the re-crystallization of
Form I from Form II and the crystallization from amorphous form and PXRD was to
confirm the polymorph transformation. Form II was prepared on a micro cover slide as
described above. The amorphous form was made the same way; the melt-quenched
amorphous solid was used prior to any crystallization. The sample was placed under a
polarized light microscope (model Eclipse E-600 POL, Nikon Corp., Garden City, NY)
with a 200× magnification lens. Images were taken using MetaMorph imaging system
(version 4.6R8, Universal Imaging Corporation, Downingtown, PA). Droplets of
solubility medium were added to completely cover the solid. Changes were monitored
visually by capturing images periodically. In the end, the cover slide with the sample on
the top (after the added liquid was removed) was loaded directly on a X-ray holder and
scanned for PXRD patterns.
Results
Solubility of APAP Polymorphs
Form I
Solubility was measured by dissolving crystals in the solubility medium at 37 °C.
The resulting clear solution phase was directly analyzed without phase separation through
centrifugation or filtration. The thermodynamic solubility of Form I was found to be 19.7
± 0.3 mg/mL in the absence of PVP, and 19.4 ± 0.3 mg/mL in the presence of PVP. The
polymer at a low concentration of 20 µg/mL did not impact the solubility of APAP in
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aqueous solution to any measurable level. These values are consistent with our previously
reported solubility using the classical solubility method.41
Form II
The thermodynamic solubility was measured from dissolving Form II crystals on
micro cover glasses. The clear solution phase was analyzed directly without
centrifugation or filtration. Eleven of these micro cover slides with no detectable Form I
by PXRD were subjected to solubility measurement at 37 °C. The solubility medium
contained pre-dissolved 20 µg/mL of PVP. After about 57–62 hours of equilibration,
seven of the eleven replicates were found to have changed to either pure Form I or mainly
Form I by PXRD, resulting in concentrations reaching or approaching the solubility of
Form I (data not shown). Data from these seven replicates were not used. However, four
replicates remained as either pure Form II or mainly Form II at the end of equilibration
(Figure 21). These four replicates maintained a higher concentration than that of Form I
up to 60 hours (Figure 22). The slight conversion to Form I in some of the Form II
replicates did not decrease the concentration at ~60 hours because substantial Form II
was still present to feed into the solution. The concentration reached for the four
replicates at time greater than 33 hours is taken as the thermodynamic solubility of APAP
Form II. The average value of the Form II solubility was calculated as 24.7 ± 0.6 (n=4),
about 5.3 mg/mL higher than Form I solubility at 37 °C. The solubility ratio between the
two APAP polymorphs is thus calculated to be 1.27 ± 0.04, which corresponds to –0.62
kJ/mole difference in free energy.
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Figure 21. PXRD patterns of residual solid recovered from solubility measurement of
Form II in 0.15 M aqueous solution of sodium chloride in the presence of 20 µg/mL of
PVP at 37 °C. The four patterns from bottom to top correspond to Form II replicate no.1
to replicate no.4 in Figure 22. Only one Form I peak was observed in three of the four
replicates as marked with the star. PXRD pattern of pure Form I is shown in Figure 30.
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Figure 22. Concentration vs time course during solubility measurement of APAP Form I
(three replicates) and Form II (four replicates) in 0.15 M aqueous solution of sodium
chloride at 37 °C.
Physical Stability of
Supersaturated APAP Solutions
Supersaturated APAP solutions in the solubility medium at concentrations at and
above solubility of Form II were studied for physical stability. Supersaturation (S) is
defined as the concentration divided by Form I solubility. Ten APAP solutions at 25 (≈
Form II solubility), 26, 27, 28, 29, 30, 32, 34, 35 and 45 mg/mL (S = 1.27x – 2.28x), each
with three replicates, were agitated at 37 °C, and the crystallization was monitored
visually. As shown in Figure 23, no crystallization was observed for up to 10 days at 25–
30 mg/mL (S = 1.27x – 1.52x), and for 4.5 days at 32–34 mg/mL (S = 1.62x – 1.73x),
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indicating that Form I is not able to nucleate from the solution at and even significantly
above the Form II solubility within the time window of the solubility measurement.
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1
2
3

45

1.78

1
2
3

35

1.73

1
2
3

34

1.62

1
2
3

32

1.52

1
2
3

30

1.47

1
2
3

29

1.42

1
2
3

28

1.37

1
2
3

27

1.32

1
2
3

26

1.27

1
2
3

25
1

2

3

4

5

6

7

8

9

10

11

Concentration

2.28

(mg/mL)

Supersaturation

Replicate

12

Time (days)
Figure 23. Physical stability of APAP supersaturated solutions in 0.15 M sodium chloride
agitated at 50 rpm and 37 °C for 12 days. Supersaturation (S) levels tested were 1.27x –
2.28x of Form I solubility (25 – 45 mg/mL). S of 1.27x (25 mg/mL) is at Form II
solubility. Green color indicates clear solutions and red color band represents the time
window during which crystallization occurred.
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MD Simulation of
APAP Polymorph Dissolution
Molecular dynamics (MD) simulations were conducted to investigate the molecular
level dissolution behavior and the solid state differences. The Form I and II virtual
crystals for MD simulation were built to match each other as closely as possible in terms
of total surface area, the numbers of APAP molecules, as well as the total length of edges
(Table 2), all of which are important in dissolution rate comparison.41 Both crystals were
placed in water boxes with additional 40 Å from each side. If the crystals were to
dissolve completely, the theoretical molar concentration would be approximately the
same (APAP I = 0.282 mM, and APAP II = 0.288 mM) that is about 2-fold of the Form I
solubility.41
The MD simulation visualized the departure of APAP molecules from the crystal
surface into the water phase, which then displayed them by thermal motions (moving
around freely in water). Images at 0, 3 and 10 ns are shown in Figure 24 to compare Form
I and Form II. As expected, most of the dissolved APAP molecules are initially located
on corners and edges for both forms (Figure 25) which has been demonstrated
previously.41 The numbers of molecules leaving the solid surface were plotted as a
function of time in Figure 26a. Under this treatment, Form I and II do not exhibit any
significant difference in the rate of dissolution. Another comparison between APAP I and
APAP II was made for the initial interaction energies for the APAP molecules located on
the corners and edges. As we have demonstrated earlier,41 the interaction energy among
the drug molecules would deter dissolution, while the interaction energy between the
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drug and water molecules would favor the dissolution. Thus the driving force for
dissolution is the difference between these two forces (total interaction energy of APAP
with water minus that of APAP with APAP), which is plotted along the x-axis in Figure
26b indicating that the driving force for dissolution for the molecules on the corner and
edge molecules are strikingly similar between Form I and Form II.

(a) t = 0

(d) t = 0

(b) t = 3 ns

(e) t = 3 ns

(c) t = 10 ns

(f) t = 10 ns

Figure 24. Display of images of two crystals from MD simulations. a to c: APAP I. (a) At 0 ns viewed down crystallographic c axis.
(b) At 3 ns. (c) At 10 ns. d to f: APAP II. (d) At 0 ns viewed down crystallographic b axis. (e) At 3 ns. (f) At 10 ns.
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(a)

(b)

Figure 25. Demonstration of the corner and edge effect in dissolution simulation of a
single crystal APAP in 0.15 M NaCl at 37 °C. Undissolved APAPs are shown in line
style and dissolved APAPs are in bulky VDW style. (a) APAP I at 10 ns. (b) APAP II at
10 ns.
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Figure 26. Numbers of molecules leaving the crystal as a function of time and the
correlation with the initial total inter- and intra-molecule interaction energies. (a)
Numbers of APAP molecules observed outside of the crystal surface from MD simulation
of stable polymorph APAP I and metastable polymorph APAP II in 0.15 M sodium
chloride at 37 °C. (b) Initial (t = 0 ns) total interaction energy difference between the
intra-molecule (APAP/water) and inter-molecule (APAP/APAP) interactions on corners
or edges. This difference is the major driving force for initial dissolution.
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Differentiation of Form I and II was noticed in the solid state during simulation. As
illustrated in Figure 24, the difference between Form I and Form II solid phases is clearly
visible. After 10 ns, the undissolved Form I solid retained its long range order shown as
well-organized crystal lattice (Figure 24-c), while the crystallinity of the remaining Form
II solid is limited only to a small area in the center, and the rest of outer layer molecules
turned into a thick mass of disordered molecules (Figure 24f). This difference was
analyzed quantitatively through two methods. Since hydrogen bonding is one of the
major forces associating molecules in crystal lattice, the H-bond profile in the solid phase
reflects the stability. The percentage of H-bonds broken over time for both crystals were
calculated (Figure 27). The stable Form I is shown to be more stable maintaining a higher
percentage of intact H-bonds. At 10 ns, 61% of the APAP II H-bonds were broken vs
41% in APAP I. Another analysis of the solid state difference is the radial distribution
function of both forms for time 0 and 10 ns (Figure 28). The decrease in the radial
distribution function indicates that the molecules have moved from their lattice positions.
APAP I retains most of the structural features at the end of 10 ns, with some difference at
≥ 17.5 Å away from the center which can be attributed to a loss of molecules in the outer
layers due to dissolution. However, APAP II displays a difference at 5 Å and beyond,
indicating the loss of crystallinity in regions close to the center of the crystal.
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Figure 27. Percentage of H-bonds broken vs time obtained from MD simulation of stable
polymorph APAP I and metastable polymorph APAP II in the aqueous solution of
sodium chloride at 37 °C.
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Figure 28. Pair correlation function calculated on the solid phases before and after
dissolution simulations in the aqueous solution of sodium chloride at 37 °C. (a) Stable
polymorph APAP I crystal. (b) Metastable polymorph APAP II crystal.
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Crystallization of APAP Form I on
Surfaces of Form II and Amorphous Solids
Surface-driven crystallization was studied by adding the solubility medium to films
of Form II or to the amorphous form on a micro cover glass. The changes were viewed
under polarized light microscopy (PLM) and further characterized by PXRD. The initial
solid was pure Form II by PXRD (Figure 29f, bottom pattern). Under PLM, Form II
crystal surface layers dissolved gradually as shown as the inward recess (Figure
29b,c,d,e) compared to time 0 (Figure 29a). During the course of dissolution, signs of recrystallization are visible on the surface starting at 20 min, becoming especially evident
at 40 min (Figure 29e). The PXRD obtained after 40 min exposure showed the appearance
of Form I peaks (Figure 29f, top pattern), which demonstrates that the surface recrystallized solid is the result of Form II to Form I transformation. More importantly, no
new crystals were observed in the solution phase, and no protruding crystals on the
surface, indicating that Form I grew from Form II on surface, a truly surface
recrystallization instead of the solution-mediated transformation. In the case of the
amorphous form (Figure 30), crystallization was observed instantaneously upon contact
with the aqueous solution (Figure 30b taken at 25 seconds). The immediate PXRD scan
(within 3 min) already showed crystallization to pure Form I (Figure 30c). This indicates
that when in aqueous solution, the amorphous material crystallizes to the stable Form I
rather than to Form II as it does in air.

a (time = 0 min)

b (time = 5 min)

c (time = 20 min)

d (time = 30 min)

e (time = 40 min)

f (PXRD before and after)

Figure 29. APAP Form II → Form I conversions studied by PLM and PXRD in 0.15 M NaCl at ambient temperature. (a) to (e) PLM
images captured at time 0 and at different times after aqueous phase was added. The part of the crystal on lower right corner was at a
different height, and therefore was not well focused. (f) PXRD patterns before (bottom) and after (top) aqueous phase was added, with
the Form I peaks marked with stars.
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a (time = 0)

b (time = 25 seconds)

c (PXRD pattern at 3 min)

Figure 30. APAP amorphous → Form I conversions studied by PLM and PXRD in 0.15
M NaCl at ambient temperature. (a) PLM image of amorphous form before aqueous
phase was added. (b) PLM image at 25 seconds after aqueous phase was added. (c)
PXRD pattern of the final solid form shown on the bottom with overlaid pure Form I and
Form II patters on the top.
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Discussion
Thermodynamic Driving Force for
Solution-mediated Polymorphic Transformation
Solution-mediated phase transformation (SMPT) is a process mechanistically
defined by three consecutive steps:17,137,18
1. Initial dissolution of the metastable phase into the solution to reach and
exceed the solubility of the stable phase;
2. Nucleation of the stable phase;
3. Crystal growth of the stable phase coupled with the continuous dissolution of
the metastable phase.
Multiple publications report that APAP Form II converts to Form I through
(SMPT).125,121,132 These observations were primarily made in crystallization solvents by
cooling a hot organic solvent solution or by adding antisolvent. 121,132,138 Our objective
was to understand how crystallization of APAP Form I occurs when Form II is added to a
solution with no APAP initially, such as in a dissolution of Form II.
How readily the stable form nucleates in step 3 of SMPT is correlated with the two
forms’ difference in Gibbs free energy, ΔG. The larger the ΔG is, the higher driving force
is for nucleation of the stable form. ΔG is a function of the activity ratio of the two solid
forms expressed in the equation of ∆

→

where R is the ideal gas

constant and T is the temperature in Kelvin. If the solubility (which approximates the
activity) of the two solid forms could be accurately measured, obtaining the ΔG value
would have been straightforward. Unfortunately, measuring APAP Form II solubility is a

121
two-decade long challenge mainly due to the facile conversion to the stable Form I in
solutions.129,130 The only available and often-cited solubility ratio of 1.3 (APAP Form II
over Form I) is from a single, short (60 min) powder dissolution test in water at 37 °C.139
In the paper, the concentration of APAP measured by UV spectrophotometry plateaued at
10 min with concentrations approaching 17 mg/mL for Form I and 22 mg/mL for Form II
(which gives the ratio of 1.3). This Form I solubility of ~17 mg/mL is not consistent with
many other publications. For example, at lower temperature of 30 °C the solubility in
water is 17.4 mg/mL,140 at 37 °C the solubility increases to 21.02 ± 0.13 mg/mL in
water141, and to 20.0 ± 0.2 mg/mL in water with 0.15 M NaCl.41 Therefore, it is probable
that saturation had not been reached at 17 mg/mL.
There have also been a number of reported attempts by calorimetry to determine the
relative stability of acetaminophen Form I and Form II.127,104,131,142 The heat capacity (Cp)
and fusion data were experimentally determined either by differential scanning
calorimetry (DSC) on the in situ melt-quenched Form II from,104 by sublimation and
solution calorimetry,127 or by adiabatic calorimetry on Form II single crystals.131 Based
on the Cp, the thermodynamic functions (enthalpy, H, and entropy, S) were derived,
which can then be used to calculate the ΔGII→I using the equation: ∆

→

∆

∆ .

The ΔGII→I from three such reports displayed a large disparity, from approximately –3.0
kJ/mole 104 to –3.9 kJ/mole127 to –13 kJ/mole131 at 25 °C, corresponding to Form II/Form
I solubility ratios of 3.3, 4.8 and 197.2 respectively. Therefore, a conclusive answer to the
energy difference (thus solubility ratio) between APAP polymorphs is still absent.
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As discussed above, the free energy difference between the two solid forms is the
key to understand the driving force of APAP Form II to I conversion in solution. The
solubility measurement is a more straightforward way to determine the free energy
difference. The challenge of obtaining accurate solubility measurements for Form II is
two-fold. The first is the difficulties in obtaining pure Form II in sufficient quantity. Form
II crystallization from ethanol was always contaminated with a small amount of Form I,
consistent with the findings from others.143 Crystallization from the melt125,143 was found
to be reliable, and pure Form II was made reproducibly. Therefore, we have adopted this
method in our study. The second challenge is the physical instability of Form II in
solution. To counter this, we applied a polymer as crystallization inhibitor to extend the
window of physical stability. A very low concentration of PVP (0.02% or 20 ug/mL) was
able to inhibit or delay the APAP form conversion without affecting the solubility in our
study. Procedurally, changes to the traditional shake flask method are necessary for this
difficult measurement. The measurement was directly performed on the micro cover glass
which avoided complications such as Form I contamination when grinding and
combining different batches. By this new method, minimal sample is required (since pure
Form II is difficult to make in large amounts), the solution phase can be collected without
filtration, and the residual solid can be easily recovered and analyzed by PXRD.
This new experimental methodology resulted in a successful solubility
measurement of APAP Form II in aqueous solution of 0.15 M NaCl at 37 °C. The Form
II solubility of 24.7 ± 0.6 mg/mL is reliable supported by the reproducibility among the
four Form II replicates (Figure 22), and most convincingly by the PXRD results
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confirming the residual solid phase collected at equilibrium being pure or mostly pure
Form II (Figure 21). Based on the Form I solubility of 19.7 ± 0.3 mg/mL measured under
identical conditions, the solubility ratio of Form II over Form I is calculated to be 1.27
± 0.04. This ratio is somewhat close to the predicted value using the Hoffman equation144
(1.2), and is quite far from the predicted value using the ideal solubility equation (1.5).145
A recent paper142 reported intrinsic dissolution rates (IDR) of 1.50, 1.33, and 1.31
mg/mL/cm2, respectively for Form II prepared by melt quenching of three different
APAP I materials (coarse, micronized and nano-silica coated), and 1.14 mg/mL/cm2 for
Form I. IDR correlates with solubility, thus an average IDR ratio of Form II over Form I
of 1.21 ± 0.09 can be calculated, which is lower but close to our measured solubility ratio
although the data are more variable and the remaining tablets were not characterized to
identify the final solid form. Our measured solubility ratio of 1.27 ± 0.04 (ΔGII→I = ca. –
0.62 kJ/mole) is significantly below the average solubility ratio (1.7) among the known
polymorph systems surveyed by Pudipeddi and Serajuddin.145 Therefore, the
thermodynamic driving force for From II to Form I conversion is quite low.
Since we have determined the solubility ratio of APAP Form II over Form I at
37 °C, we can now address the question: Is the dissolution of Form II able to reach the
supersaturation level required for Form I to crystallize? Figure 23 demonstrates that Form
I is not able to crystallize from solutions at supersaturations of 1.27x – 1.52x over Form I
solubility (1.27x is at Form II solubility) over the course of up to 10 days of agitation at
37 °C. Form II would have had ample time to dissolve and reach saturation before Form I
is crystallized from the solution. But the reality is the opposite. This strongly suggests
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that primary nucleation through solution-mediated polymorphic transformation is not the
mechanism dictating the facile APAP Form II to Form I conversion in solution. The rapid
conversion from Form II to Form I in solution must be due to other reasons.
MD Simulation of Differences
between APAP Polymorphs during Dissolution
Simulated dissolution profiles of APAP I and APAP II nanocrystals (4.6–4.7 nm as
shown in Table 2) were constructed. The numbers of molecules leaving the crystal sphere
were found to be almost identical between the two crystals within the 10 ns simulation
(Figure 26a). This appears to contradict the thermodynamic stability relationship of the
stable Form I vs the metastable Form II at 37 °C. However, nanoparticles with sizes down
to <100 nm can increase saturation solubility,114 and our calculation indicated a 3.4-fold
solubility increase when the particle size is reduced to 4.6 nm.41 This 3.4 folds higher
solubility could attenuate the difference between the two forms if such a difference is
small to start with. More importantly, we have demonstrated41 that the initial dissolution
rate is profoundly affected by the corner and edge effect (molecules at corners and edges
dissolve first). In nanocrystals of APAP I and II, the molecules that dissolve within 10 ns
came mainly from on the corners and edges (Figure 25a,b). A much higher percentage of
molecules become edge or corner bound when the crystal is nanosized rather than
macroscopic. Therefore, the corner and edge effect dominates the initial dissolution of a
tiny nanocrystal. Further, the driving force for dissolution is the strength of drug
molecule interaction with water being greater than drug-drug molecule binding energy.41
This driving force is favorable since the net interaction energies are negative (Figure
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26b). A striking closeness between Forms I and II was observed, with comparable net
interaction energy values residing in the edges (–14.8 kJ/mole for Form I and –14.1
kJ/mole for Form II), as well as in the corners (–77.4 kJ/mole for Form I and –83.8
kJ/mole for Form II). The similar initial dissolution rate of Form I and II nanocrystals can
thus be adequately explained by the similar dissolution driving force inherent in the
corner and edges molecules which are the first dissolved molecules. The 3.4x saturation
solubility increase over the normal size crystals further masked the real but small
difference between the solubility of these two solid forms.
The second analysis of the MD simulation data was to examine the differences in
the remaining solid phase between APAP I and II. The results are consistent with the
thermodynamic stability relationship. APAP II crystal is less stable than APAP I as
shown by higher percentage of H-bond broken (Figure 27) over time. H-bonding is the
major force contributing to lattice energy. Fewer H-bonds are associated with a decrease
in the heat of fusion of the crystal. The van der Waal forces (the other major force for
molecular association) is also expected to be smaller in APAP II based on the visibly
more disordered lattice in Figure 24c,f. Furthermore, not only the corner and edge
molecules but also those on the flat surfaces in APAP II have turned into a disordered
state. The visible thick disordered layer surrounding the APAP II crystal was determined
by pair correlation function (Figure 28) to be significant. The dense drug layer represents
a high concentration of APAP molecules on the crystal surface. This discovery pointed
out a link between crystal surface and Form I crystallization rate.
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Facile APAP Form II to Form I Transformation
through a Surface Facilitated Mechanism
Based on the insight gained from the MD simulations, the Form II surface is poised
to offer the supersaturation which the kinetics of Form I crystallization heavily depends
on. The visual PLM experiment on Form II dissolving into aqueous solution (Figure 29ae) provides direct evidence of the involvement of the surface layer in the Form II to Form
I transition. While the surface of Form II showed evident signs of re-crystallization
(which was confirmed by PXRD to be Form II to Form I transformation), the solution
phase appears to be completely clear without any nucleation and crystal growth.
Furthermore, the conversion on the surface took place relatively quickly; in a matter of
~40 min, Form I peaks were already present in PXRD pattern (Figure 29f). This indicates
that the surface has cultivated the polymorphic transformation.
Based on the data presented in Figure 29, it can be deduced that the concentration
on Form II surface has to be much higher than a supersaturation of 1.52x over Form I
solubility, or else the nucleation of Form I could not have taken place rapidly. It is
reasonable to believe that such a highly concentrated APAP layer on the Form II surface
is created due to the fact that the hydration rate is faster than the molecular diffusion rate
from the surface to bulk solution phase. The existence of the high supersaturation sets the
stage for potential polymorphic conversion. This phenomenon presumably also exists in
other metastable solid systems, but why does it lead to fast solid form conversion in the
APAP system? This can be interpreted by the crystallization tendency of APAP. APAP
was reported to crystallize from the amorphous state more readily than other studied
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compounds due to lower configurational entropy and higher molecular mobility.

Lower configurational entropy means higher probability to assume proper orientation and
conformation for crystal nucleation, which is intrinsic to the molecular structure of
APAP. The molecular mobility, on the other hand, is expected to increase drastically in
the dissolution study when compared to the dry amorphous system since water is
introduced. Therefore, on the highly supersaturated surface, APAP should have a high
tendency to nucleate. This is supported by the data in Figure 30a,b where the amorphous
phase of APAP crystallizes almost instantaneously once in solution. More specifically, at
the hydrated amorphous surface which mimics the highly concentrated APAP molecule
layer accumulated on Form II surface observed by MD simulation, it was the stable Form
I that has been crystallized. The resultant PXRD pattern represents an unequivocally pure
Form I (Figure 30c). These data imply that the highly concentrated APAP layer on the
Form II surface has facilitated the Form I crystallization.
The evidence presented above leads to the conclusion that the APAP Form II to I
conversion in solution is through the surface-facilitated phase transformation (SurFPT),
as opposed to the well-known solution-mediated phase transformation (SMPT). We
envision the steps of SurFPT (Figure 31) in the following sequence: (a) The Form II
surface molecules hydrate immediately once the water is introduced; (b) The hydrated
molecules remain on the surface because of the barrier to diffuse into the bulk; (c) The
concentration on the surface becomes high enough to crystallize as Form I.
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Figure 31. Schematic Illustration of Surface Facilitated Phase Transformation (SurFPT).
The metastable form hydrates immediately once the water is introduced. The hydrated
molecules quickly accumulate on the surface, approaching a high enough supersaturation
level which leads to crystallization into the stable solid form.
As in SMPT, the presence of solvent (water in our study) is a prerequisite for
SurFPT. Contrary to SMPT, however, in SurFPT the nucleation takes place on the
metastable crystal surface coated with rapidly solvated drug-rich layer rather than in the
solution. Sometimes, SMPT could nucleate on foreign particle surfaces (heterogeneous
nucleation), however, the crystal growth usually is toward the solution phase creating
protruding crystals147 because the solution phase is supplying the molecules. In the case
of SurFPT, the crystal grows beneath the surface (Figure 29) following the seeding by the
surface layer crystals. Since accumulation of drug concentration on the surface takes a
shorter time, SurFPT mechanism promotes a faster polymorphic conversion for drugs
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with higher intrinsic tendency for crystallization, such as APAP. Finally, it can be safely
extrapolated that the SurFPT mechanism also should be responsible for the reported
APAP Form II to Form I conversion in air under different relative humidity conditions.143
Since the SurFPT mechanism could be used in other polymorphic systems, its
implication goes beyond the APAP polymorphic pair. Understanding SurFPT benefits
formulation and solid state scientists in the research and development of pharmaceutical
products. For examples, in the effort to make metastable forms or to measure solubility of
metastable forms or to use metastable form to gain solubility advantage, SurFPT is far
more detrimental than SMPT. This has caused the failure in measuring the solubility of
APAP Form II in the past and in preparing APAP Form II on a large scale which
otherwise would provide a lower cost option for processing solid dosage forms. It would
also decrease the solubility advantage of a metastable form when the drug is taken in
vivo, because the solid does not have any chance to dissolve into solution within the
absorption window before the stable form crystallizes. The outcome is analogues to the
matrix crystallization occurring in amorphous solids which negated the dissolution
advantage of the amorphous form.19
Conclusions
We presented strong evidence from a series of molecular dynamics simulations and
experiments that reveal the root cause for the facile polymorphic conversion of APAP
from orthorhombic Form II to monoclinic Form I. APAP Form II undergoes surfacefacilitated phase transformation (SurFPT) in contact with the solution. In SurFPT, the
nucleation takes place on the metastable crystal surface coated with rapidly solvated
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drug-rich layer rather than in the solution where creating sufficient supersaturation takes
a longer time. From MD simulations, such a drug-rich layer is evident on the APAP Form
II surface but not on the Form I surface. The SurFPT mechanism we have demonstrated
with APAP could also exists in other polymorphic systems. This mechanism promotes a
faster polymorphic conversion for drugs with higher intrinsic tendency for crystallization,
such as APAP. Understanding it helps us select appropriate strategies to circumvent the
polymorphic conversion problems during manufacturing of active pharmaceutical
ingredients and drug products.
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CHAPTER FIVE
DRUG–POLYMER INTERACTIONS AT WATER-CRYSTAL INTERFACES AND
IMPLICATIONS FOR CRYSTALLIZATION INHIBITION: MOLECULAR
DYNAMICS SIMULATIONS OF AMPHIPHILIC BLOCK COPOLYMER
INTERACTIONS WITH TOLAZAMIDE CRYSTALS
Abstract
A diblock copolymer, PEG-b-PLA, is effective in modulating the crystal growth of
tolazamide, resulting in a crystal morphology change from needles to plates in aqueous
media. To understand the molecular mechanism of this crystal surface drug–polymer
interaction, we conducted molecular dynamics (MD) simulations on crystal surfaces of
tolazamide in water containing PEG-b-PLA. To ensure that the polymer structure was
fully equilibrated, a 130 ns simulation of the polymer in a large water box was run before
initiating 50 ns simulations with each of the crystal surfaces. The simulations
successfully demonstrated the differentiated drug–polymer interactions and are consistent
with experimental studies. Interaction of PEG-b-PLA with the (001) face occurred more
rapidly (≤10 ns) and strongly (total interaction energy of –29.1 kJ/mole/monomer) than
that with the (010) face (~35 ns, –21.02 kJ/mole/monomer). In addition, there was
virtually no interaction with the (100) face. Interestingly, upon dissecting the various
contributions to the total interaction energies, van der Waals interactions were identified
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as the dominant forces (accounts for 77–93% of total interaction energies) that enabled
such strong drug–polymer interactions. It suggests that polymers capable of forming
strong hydrophobic interactions are more effective in inhibiting crystallization of poorly
water-soluble and hydrophobic drugs in aqueous media (such as gastrointestinal fluid)
than those with hydrogen bonding capacities. Such in-depth analysis and understanding
facilitate the rational selection of polymers in designing supersaturation-based enabling
formulations.

Key words: Tolazamide, poly(ethylene glycol)-block-poly(lactic acid), molecular
dynamics simulation, crystallization inhibition by polymers, drug-polymer interaction,
crystal surface specific interactions, crystal morphology modification, van der Waals
interaction.
Introduction
Synthetic and natural polymers have been widely used in developing and manufacturing
pharmaceutical products. The applications include148,149 (but are not limited to) binding
the particles of a solid dosage form, changing the flow properties of active
pharmaceutical ingredient (API), masking unpleasant taste of a drug, modifying drug
release characteristics, stabilizing suspensions, enabling drug delivery and inhibiting
crystallization of APIs. The ability of polymers to inhibit crystallization of drug
molecules has promoted intense research in recent years. Polymers are used to stabilize
the metastable solid form in formulations, i.e. amorphous solid dispersions (ASD150-152),
to deliver poorly water-soluble small molecular drugs (Class II and IV in
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Biopharmaceutics Classification System ) which represent approximately 90% of
current pipeline drugs across the pharmaceutical industry.154 Polymers also are used to
maintain supersaturation during dissolution of enabling formulations for maximizing
formulation performance.19,155-157 Finally, polymers can play an important role in
modifying the crystal habit during solution crystallization.158-160
Crystallization inhibition originates from drug–polymer interactions. Understanding
the mechanism of how drug molecules interact with a polymer will help us to select a
better polymer for formulating and delivering drug molecules. Molecular dynamics (MD)
simulations are well suited for adding insights that would otherwise difficult to gain by
experimental methods. The reported use of MD simulation in drug crystallization
inhibition by polymers can be divided into two main areas: polymer–drug interactions in
amorphous systems which primarily deal with solubility or miscibility58-63 and crystal
systems which address crystal growth inhibition. In the latter, there are only a few
published studies in recent years. Zhu et al. simulated the interaction of several additives
(such as hydroxypropyl methylcellulose, HPMC) in water with crystal surface of
fenofibrate66 and griseofulvin.65 A short HPMC chain (five repeating units) was
constructed and placed into a small water box (1500 water molecules) with the simulation
carried over a short duration (600–800 ps). The simulated binding energies between the
additives and crystal surface were correlated with the experimental results when these
additives were found to reduce the particle size of recrystallized griseofulvin. In 2012,
Yani, Chow and Tan reported a 400 ps MD simulation of large polymers (225 monomers
for PVP and 62 for HPMC) with different crystal phases of salbutamol sulfate in
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vacuum. Hydrogen bonding between PVP and salbutamol sulfate, which was ~40% of
64

the total binding energy, was thought to dominate in prohibiting crystal growth. The
water soluble polymers used in drug crystallization inhibition strongly interact with water
molecules. As a result, the interaction with drug molecules is expected to change in the
presence of water. For examples, Taylor and her group reported that
poly(vinylpyrrolidone) (PVP), which is an effective crystallization inhibitor to felodipine
in amorphous solid dispersions at low relative humidity (RH) significantly reduced its
effectiveness at high RH161 and even lost its ability in aqueous dissolution medium.162
The loss of effectiveness was ascribed to the strong interaction of PVP with water
molecules. Apparently, more studies are needed to improve upon the MS simulation
methodologies (i.e. sufficiently long simulation time under more realistic conditions) in
order to demonstrate the validity and utility of MS simulation as an emerging and
powerful technique for such applications. More importantly, it is necessary to conduct
more careful analysis in interaction energies involved in the drug–polymer interaction for
the purpose of understanding the mechanism of crystallization inhibition by polymers in
aqueous solutions. The purpose of our present work, therefore, is to develop improved
MD simulation methods to study the molecular level mechanism and energetics involved
in crystal growth inhibition by polymers in an aqueous solution.
The model system chosen for this study is comprised of tolazamide (TLZ), an oral
hypoglycemic agent, and poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA), an
amphiphilic block copolymer. Based on the interesting work published by Kuldipkumar
et al,158,163,164 PEG-b-PLA selectively interacted with the (001) phase of the TLZ crystal,

changing the crystal habit from needle to plate shape
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(shown in Figure 32). PEG-b-

PLA exerts this strong habit modification at very low concentration (3–10 ppm)
regardless of PEG to PLA monomer ratios in the polymer.164 Atomic force microscopy
with the tip tethered with the polymer or parts of the polymer (PEG or PLA) determined
the adhesion forces to individual faces of the single crystals. The adhesion forces were
the strongest (264 nN) with (001), the weakest (~5 nN) with (100) and intermediate (170
nN) with (010).164

(a)

(b)

Figure 32. Tolazamide crystals obtained (a) in the absence of PEG-b-PLA and (b) in the presence of 50 µg/mL of PEG-b-PLA.158
(Photomicrographs used with the permission of Crystal Growth and Design).
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Our MD simulation was designed to investigate the interactions between TLZ
crystals and PEG-b-PLA in water. Large crystal surfaces of (001), (010) and (100) were
built respectively into a sizable water box. A representative PEG-b-PLA was constructed,
first equilibrated with a 130 ns MS simulation in water and then added to another water
box containing the crystals. The assembly was simulated for 50 ns to determine how the
polymer molecule interacts with each crystal surface. The nature of the polymer
interaction with TLZ molecules was quantitatively determined through van der Waals
and electrostatic interaction energies. The results from the study strongly correlated with
the reported experimental data, allowing an in-depth view of how the molecular
interactions responsible for the crystallization inhibition take place at the crystal-water
interface. This correlation with experimental results established our MD simulation
method, which will allow future applications of this method in studying other drug
crystal–polymer interactions.
Experimental
Building the Crystals
The single crystal structure of tolazamide (TLZ, molecular structure in Figure 33a)
was taken from CABCUD01165 in the Cambridge Structural Database (Cambridge, UK).
The crystal system is triclinic with space group P1, Z = 2 and a = 6.355 Å, b = 9.223 Å, c
= 13.510 Å, α =101.104°, β = 92.80 ° and γ = 85.72° (Figure 33b). The molecules are
dimerized by NH-O hydrogen bonds and dimers are packed together through van der
Waals interactions only.165 TLZ is poorly water-soluble (intrinsic solubility of ~70
µg/mL), hydrophobic (CLogP of 2.69) and weakly acidic (pKa of 5.9 assigned to the

sulfonamide hydrogen).
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Three virtual crystals were constructed from the unit cell

using Mercury software (Mercury 2.3, CCDC 2001-2009) following our previous
method41 with some modifications. The (001) surface crystal was built by extending the
unit cell at a, b, and c directions for 17, 2 and 8 times, producing the 17 x 12 x 2 crystal
lattice. Similarly, the (010) and (100) surfaces were made at 17 x 2 x 8 and 2 x 12 x 8
unit cell repetitions (detailed in Table 3 and Figure 34).
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Figure 33. (a) Molecular structure of tolazamide. (b) Unit cell of tolazamide. (c)
Molecular formula of PEG-b-PLA.

Table 3. Three Crystal Lattices of Tolazamide Built with large (001), (010) and (100) Surfaces.

Lattice with

Crystal Dimension (Å)

Surface Size

Surface

no. of molecules
unit cells
a

b

c

× 104 (Å2)

(001)

17×12×2

108.04

110.68

27.02

816

1.19

(010)

17×2×8

108.04

18.45

108.08

544

1.17

(100)

2×12×8

12.71

110.68

108.08

384

1.17
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(a) (001) surface

(b) (010) surface

(c) (100) surface

Figure 34. Illustration of the tolazamide molecular packing on three surfaces of crystals
used in simulation. (a) (001) surface with the flat face of the methyl benzene ring toward
water. (b) (010) surface with the methyl benzene ring oriented toward water
perpendicularly. (a) (100) surface with the azepane ring toward water perpendicularly.
The crystals constructed above were prepared using Visual Molecular Dynamics
software (VMD, version 1.9, March 2011).99 The topology and parameters of TLZ for the
CHARMM2739 force field were obtained from the Swiss Institute of Bioinformatics
(http://swissparam.ch/). The structure file of the crystals was built using the Automatic
PSF Builder function in VMD from the input of the Mercury coordinate file and the TLZ
topology file.
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Building the Polymer and
Obtaining the Hydrated Polymer Structure
The polymer used was a poly(ethylene glycol)-block-poly(lactic acid) (PEG-bPLA) (general formula shown in Figure 33c), within the class of amphiphilic diblock
copolymers. The PEG-b-PLA polymer built for this study contains 22 and 8 repeating
units of PEG and PLA, respectively, mimicking a PEG: PLA ratio of 110: 40 in a
commercially available PEG-b-PLA polymer which was used in the reported TLZ habit
modification study.164 The molecular weight of PEG22-b-PLA8 is 1600 g/mol, or 20% of
the real polymer. The chemical structure was drawn using ChemDraw (ver 9.0.7,
Cambridge, Massachusetts) which was then input into Spartan O2 (Wavefunction, Inc.,
Irvine, California) to calculate the three-dimensional molecular structure in mol2 format.
This was submitted to Swiss Institute of Bioinformatics (http://swissparam.ch/) to obtain
the topology and parameters for the CHARMM2739 force field.
Prior to simulating the polymer-crystal surface interaction in water, the polymer
must be equilibrated with water. This was accomplished through a 130 ns MD simulation
in water. The steps of energy minimization and production run followed the conditions
described in the following section. The polymer was first simulated in a 64×62×53 Å
water box for 100 ns, and then in a larger size water box (106×118×114 Å) for another 30
ns. The polymer structure from the end of 130 ns was combined with that of the crystals
to simulate the polymer crystal interactions in a water box.

142
Building the Polymer
and Crystals together in Water
Water rather than buffer was selected as the aqueous medium in this simulation
since neither the rate of crystallization nor the morphology of TLZ in the presence of
PEG-b-PLA was affected by changing buffer pH values.164 The hydrated PEG-b-PLA
polymer structure and TLZ crystals were built together using VMD software (version 1.9,
March 2011).99 The center of the polymer was positioned at 20 Å away from the center of
each crystal surface, and about 4.9×104 water molecules (~100 Å distance from the
crystal surface) were added to cover the crystal surface and the polymer. The combined
structural files were created using the Automatic PSF Builder function in VMD.99
MD Simulation
The computer code used for the MD simulations was the parallel, scalable MD
program NAMD version 2.9b1.100 Periodic boundary conditions were used. The cutoffs
for nonbonding (van der Waals and electrostatic) interactions were 12 Å. The switch
distance was 10 Å, and a 1.0 1–4 scaling factor was used. The polymer and crystal in the
water box were first subjected to energy minimization (6000 steps) followed by slow
heating from 10 to 298 K over 30000 steps. The temperature and pressure of the system
were equilibrated for 10000 steps using a Langevin piston. The system was then allowed
to equilibrate for 30000 steps at constant temperature (298 K) and pressure (1 atm). After
equilibration, the crystal was fixed so that it does not dissolve into water in the following
production run so that the polymer’s interaction with the intact crystal surface can be
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simulated. Production simulation of the polymer interaction with the intact crystal surface
was performed at constant volume and temperature (298 K) for 50 ns.
Analysis of MD Simulation Data
Simulated results were viewed using VMD (version 1.9, March 2011).99 Interaction
energies were calculated using algorithms for the van der Waals (VDW) and electrostatic
energies in the NAMD program.100 These calculations were performed for the whole
polymer (PEG22-b-PLA8) and the PEG22 and the PLA8 portions of the polymer within
4 Å of the TLZ molecules. Because partial charges exist in an atom due to the different
electronegativities of the atoms, the potential function used in the molecular dynamics
simulation considers the partial charge in every atom even when the molecules are
neutral. The electrostatic interactions, including ion–dipole interactions and H-bonding,
and van der Waals interactions, including London dispersion forces and electronic
repulsions, were calculated using the partial atomic charges and van der Waals
parameters in the CHARMM potential function.39 Since the block polymer contains more
PEG repeating units than PLA, the interaction energy was reported as energy value per
monomer. This allows comparison in interaction strength among polymers with different
chain lengths.
Results
Visual Analysis
Surface (001)
Initially the polymer moved freely in water but quickly (at 0.5 ns) it approached the
surface (Figure 35a). At 2 ns the PLA tail made a contact with the surface (Figure 35b).
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The polymer bent toward the surface (Figure 35c). At 4.5 ns, the PEG tail also touched
down (Figure 35d). Both PLA and PEG ends gradually pulled the whole polymer down
to the surface (Figure 35e,f). At 10 ns the polymer flattened itself on the surface (Figure
35g), after which there were no further position changes through the end of the 50 ns
simulation (Figure 35h), although the polymer kept making small movement (vibrating)
from 10 to 50 ns. A view from the top of the crystal surface at 50 ns (Figure 35i) shows
the polymer lays curled and flat on the surface. It appears that the tails of the polymer
play a bigger role in initiating the interaction than the other parts of the polymer.

145
(a) t = 0.5 ns

(b) t = 2 ns

(c) t = 3.5 ns

(d) t = 4.5 ns

(e) t = 6.5 ns

(f) t = 8 ns

(g) t = 10 ns

(h) t = 50 ns

(i) t = 10 ns, top view

Figure 35. Display of images of MD simulation of PEG-b-PLA polymer with TLZ crystal
surface (001) at different times. PLA portion is shown as red/blue/white (oxygen is red,
carbon is blue and hydrogen is white). PEG as red/beige/pink (oxygen is red, carbon is
beige and hydrogen is light pink). For clearer views, water molecules are not shown.

146
Surface (010)
The polymer behaved differently with the (010) face. The PEG tail was already at
the surface at time 0 (Figure 36a) indicating this has occurred earlier during the
equilibration. However, the faster interaction with the PEG tail did not bring about any
faster interaction with the whole polymer. During the period of 0 to 20 ns, there has been
simply a single contact between the PEG end and the surface (Figure 36b,c), while the
PLA part moved around in the water phase. Changes finally took place at 23 ns when the
PEG chain gradually lowered to the surface (Figure 35d,e). At 50 ns (Figure 35f), most of
the PEG lied down as a linear chain, but is not coiled as on the (001) surface. As seen
with the (001) surface, the initial contact with the crystal surface was made through the
tail of the polymer. Interestingly, only a small part of PLA made contact with the (010)
surface.
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(a) t = 0 ns

(b) t = 10 ns

(c) t = 20 ns

(d) t = 23 ns

(e) t = 30 ns

(f) t = 50 ns

Figure 36. Display of images of MD simulation of PEG-b-PLA polymer with TLZ crystal
surface (010) at different times. PLA portion is shown as red/blue/white (oxygen is red,
carbon is blue and hydrogen is white). PEG is shown as red/beige/pink (oxygen is red,
carbon is beige and hydrogen is light pink). For clearer views, water molecules are not
shown.
Surface (100)
The polymer did not interact with the (100) face. From 0 to 10 ns, the polymer
sometimes moved closer to the surface (Figure 37a), and sometimes moved further away
(Figure 37b). Starting from 12 ns it gradually diffused from the center toward the edge of
the water box (Figure 37c). The polymer moved across the (100) surface until it found the
(001) face at ~17 ns (Figure 37d). Evidently the polymer has little affinity to (100) but its
binding to (001) is favored. The polymer settled on the edge of (001) and (100) at 35 ns

148
(Figure 37e) with no changes afterwards. The PEG part interacted with (001) phase,
while the PLA part found a space on the edge between (001) and (100) (Figure 37f).
(a) t = 1 ns

(b) t = 4 ns

(c) t = 15 ns

(d) t = 17 ns

(e) t = 35 ns

(f) t = 35 ns, enlarged

Figure 37. Display of images of MD simulation of PEG-b-PLA polymer with TLZ crystal
surface (100) at different times. PLA portion is shown as red/blue/white (oxygen is red,
carbon is blue and hydrogen is white). PEG as red/beige/pink (oxygen is red, carbon is
beige and hydrogen is light pink). For clearer views, water molecules are not shown.
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Interaction Energy Analysis
Interaction energies between each block of the polymer (PLA or PEG) and the three
crystal surfaces were calculated to characterize how the crystal surface differentiated
interactions with the polymer. The energy level was normalized by the number of
monomers in each block in order to compare PLA with PEG. Six plots demonstrating the
dynamic changes in VDW and electrostatic energies as a function of simulation time are
shown in Figure 38.
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(a) (001) face

(b) (001) face

(c) (010) face

(d) (010) face

(e) (100) face: 0–17 ns

(f) (100) face: 0–17 ns

Figure 38. The interaction energies vs time between the polymer (including PEG portion,
PLA portion and the whole polymer PEG-b-PLA) and the three TLZ crystal surfaces
calculated as VDW and electrostatic energy per monomer in both blocks of the polymer.
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The onset of increase in interaction energy in Figure 38 exactly coincided with the
visually observed polymer-crystal interactions (Figure 35, Figure 36 and Figure 37).
Since interaction energy levels plateau after 35 ns, it can be assumed that the interaction
between the polymer and the surfaces had approximately reached equilibrium, and the
degree of interaction could be estimated by the averaged energy values from 35 to 50 ns
for both VDW and electrostatic forces. When the VDW of the whole PEG-b-PLA is
compared at equilibrium, (001) phase shows significantly stronger interaction (–
27.1 ± 1.8 kJ/mole of monomer) than that of the (010) surface (–16.4 ± 1.7 kJ/mole of
monomer). When PEG and PLA are compared separately, at the (001) face both PLA and
PEG portions contributed to the VDW energy (Figure 38a), while at the (010) surface the
PEG portion provides the major contribution since the PLA hardly interacted with (010)
(Figure 36). There is no interaction with the (100) face for either portion of the block
polymer (Figure 38e,f).
The van der Waals interaction energy obtained is much larger than the electrostatic
interaction energy. This is true regardless of crystal faces and different parts of the
polymer. In addition, the electrostatic interaction is mostly contributed by the PLA part.
Discussion
Dependence of Drug Molecular Packing
on Drug–Polymer Interactions
The MD simulation indicates that PEG-b-PLA in water interacts most strongly with
the TLZ (001) phase (Figure 35 and Figure 38a,b), less strongly with the (010) face
(Figure 36 and Figure 38c,d) and almost not all with the (100) face (Figure 37 and Figure
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38e,f). This is consistent with reported experimental results that the adhesion forces
between the polymer and TLZ crystal faces followed the rank ordering of (001) > (010) >
(100) with very low measurable forces toward (100).164
Intuitively the surface differentiated interaction is due to different TLZ molecular
packing on the crystal surface since it is the only variable in the simulation experiment.
On the (001) face, the methyl phenyl ring lays almost flat on the surface (Figure 34a),
providing larger effective surface area to interact with the polymer. When the polymer
molecular comes in contact with the (001) face, the sheet of benzene rings offer strong
interactions (i.e. van der Waals and hydrophobic interactions). The total van der Waals
interaction energy with (001) per monomer exceeded –27 kJ/mole (Figure 38a) which
leads to stable interactions once contact is made between the polymer and the surface.
Within 10 ns, the polymer has already fully coiled on the (001) surface.
The (101) surface also consists of the methyl phenyl ring; however, the ring “stands
up” with the methyl group pointing outward (Figure 34b). When the polymer comes to
this surface, it first encounters the methyl group that is expected to provide fewer VDW
and hydrophobic interactions with the polymer. The polymer has to penetrate deeper in
order to interact with the benzene ring which takes longer time. The total van der Waals
interaction energy per monomer decreased to –16.4 kJ/mole on (010) (Figure 38c), a 40%
reduction compared to that on (001). This may have contributed to the much slower
interaction. Since the weaker interaction compared to the (001) face allows for more
movement after contact is made, it took 35 ns for the PEG chain to bind to the (010)
surface. Interestingly, the PLA part could not find a place to “lay down” on (010) after
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“searching” for 50 ns. This is quite different than the fast and tight binding between PLA
and (001). The details of the interface of water–polymer–(001) surface at 50 ns is shown
in Figure 39. Parts of the PLA chain snuggly fit into the gaps formed between two layers
of the methyl phenyl ring. On (010), the surface molecules appeared to be more mobile
and did not form a groove to accommodate the PLA chain (Figure 36f). Thus, there is less
interaction of the PLA with the (010) surface.

Figure 39. Enlarged image at (001) crystal–water interface to demonstrate the PEG-bPLA polymer–TLZ interaction at 50 ns. The PLA part is located at the left side (color
code of the atoms: oxygen is red, carbon is blue and hydrogen is white). The PEG part is
at the right side (color code of the atoms: oxygen is red, carbon is beige and hydrogen is
light pink).
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Lastly, on the (100) surface, the dominant molecular moiety is the azepane
perpendicularly facing the water phase (Figure 34c). The van der Waals interactions to
hydrocarbons on the azepane are expected to be weaker compared to the phenyl rings.
This perhaps explains the lack of the polymer interaction with the (100), and why the
polymer prefers to move toward (001) which is adjacent to (100) and interacted with the
(001) face instead.
The simulations were able to visualize the crystal surface specific interactions, thus
providing direct evidence for understanding the crystal growth inhibition by polymers. As
described in the diffusion theory for crystal growth,25 the overall crystal growth rate in a
first order process is controlled by the rate of molecular diffusion from the bulk solution
to the crystal surface and the rate of molecule integration into the crystal surface. Alonzo
et al.32 have found that in the presence of HPMC, felodipine crystal growth shifted
toward an integration-controlled mechanism from the diffusion-controlled mechanism.
The visual findings from the simulations support the role of polymers in reducing surface
integration rate. The observed rapid and strong adsorption of the PEG-b-PLA selectively
to (001) provides physical blockage for other TLZ molecules to integrate into the (001)
surface for extending the crystals in the (001) direction. This resulted in the TLZ
morphology change (Figure 32). However, the polymer–crystal surface specific
interaction does not inhibit crystallization because some surfaces are not inhibited and are
still free to grow. The MD simulation is potentially a method to screen polymers for
intended purposes. For example, if crystal habit modification is needed, the screening
will look for specific crystal surface interaction with different polymers. If the objective
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is to inhibit crystal growth at all or to obtain significantly reduced particle size, the
screening can target the polymers with a universal inhibition across different crystal
surfaces. Applying MD simulation for such an application may become a reality
relatively sooner due to advances in MD simulation methodology and rapid increases in
computational speed.
Importance of VDW Forces in
Polymer–Crystal Surface Interaction
The MD simulations demonstrate the important role of VDW forces in TLZ–PEGb-PLA interactions. Most oxygen atoms (shown as red in Figure 39) in the polymer are
oriented toward water, while the atoms on the hydrocarbon chain which are hydrophobic
are tightly inserted into the layers of phenyl rings on the (001) face. Thus, the polymer
forms hydrophilic and H-bond interactions with water molecules but hydrophobic and
van der Waals interactions with the TLZ surface molecules.
The visual observation in Figure 39 is quantitatively captured in Figure 38 where
the interaction energy landscape between the polymer and TLZ molecules is presented.
The electrostatic interaction energy (Figure 38b,d,f) is small compared to VDW
interaction energy (Figure 38a,c,e). The electrostatic energy, including hydrogen
bonding, only accounts for 7.0% of total interaction energies between PEG-b-PLA and
(001) (2 out of 29 kJ/mole), 23% of that on (010) (4.8 out of 21.3 kJ/mole), and 15.6% of
that on (001) at the (001/(100) edge (3.8 out of 24.0 kJ/mole). The small electrostatic
interaction is mainly contributed by the PLA block and minimally by the PEG block.
This conforms to the chemical structures of the PEG-b-PLA and TLZ. Only one
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hydrogen atom at the PLA tail can be donated to form a hydrogen bond (Figure 33c). The
rest of polymer has multiple hydrogen bond acceptors. The carbonyl oxygen in PLA is a
stronger hydrogen acceptor than the ether oxygen in PEG because it is more
electronegative. In the TLZ crystal, the methyl phenyl ring on (001) and (010) faces or
the azepane on (100) face do not possess strong H-bond donors or acceptors. TLZ
molecules in the crystal are dimerized by intermolecular NH–O hydrogen bonds165 which
are not accessible from the surfaces. These data indicate that hydrophobic interactions
rather than hydrophilic interactions are responsible for most polymer–TLZ intermolecular
interactions.
The above conclusion for TLZ can be applied to many other poorly water-soluble
compounds for several reasons. Firstly, more than two third of the marketed poorly
soluble drugs (219 out of 318 BCS Class II and IV compounds) surveyed in 2011 are
highly hydrophobic (CLogP > 2.50), similar to or more hydrophobic than TLZ
(LogP = 2.69).166 When placed in a polar environment (i.e. water), these non-polar
molecules will have a tendency to group together with the non-polar motif of the polymer
to minimize the surface area in contact with water. This is the nature of hydrophobic
interactions. Therefore, for these crystal surfaces, formation of hydrophobic interaction
with polymers would be much more energetically favorable.
Another important factor to consider is the role of water. The interaction of a
polymer with a drug in dry state (i.e. in amorphous solid dispersion where H-bonding
with polymers is important for physical stability) changes when water is introduced.
Formation of drug–polymer H-bonds in aqueous solutions should be less favorable due to

157
the strong competition from water. Since water is 55 M and an excellent H-bond donor
and acceptor, it would dominate the H-bond sites on the crystal surface as well as on the
polymers. An MD simulation study on adsorption of polyethylene glycol (PEG) on the
surface of dicalcium silicate showed that the absorption energy decreased more than 10fold in the presence of water compared to under vacuum due to the added interaction of
water with the PEG and dicalcium silicate.167
Thirdly, the VDW interactions are not as weak as often perceived. Although
hydrogen bonding (bond energy of 8–30 kJ/mole)168 is in general stronger than VDW
forces (bond energy of 4–41 kJ/mole)168 on a per interaction basis, the total interaction
energy from the VDW forces could overwhelm the contribution from hydrogen bonding
due to the larger numbers of VDW interactions. The sum of many VDW interactions can
be very strong as exemplified in the TLZ and PEG-b-PLA system where the VDW
interaction energy with the (001) face is 27.1 kJ/mol/monomer (Figure 38a), reaching the
level of a strong H-bond (O–H→O bonding energy is 25 kJ/mol).168 This explains how a
ppm level of PEG-b-PLA was able to block the (001) surface growth.158
The lack of experimental techniques to accurately measure the level of hydrophobic
interactions between the polymer and the drug may have been why the hydrophobic
interactions have not been emphasized in the past. Recently more work has recognized
the role of hydrophobic interactions in crystallization inhibition. In 2013, IIevbare et
al.169 reported a comprehensive study on the crystal growth rate of three structurally
diverse hydrophobic drugs (celecoxib, efavirenz, and ritonavir) in the presence of 22
different polymers in aqueous solution. Despite the different chemical properties and
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structures of the model compounds, nonspecific hydrophobic drug−polymer interactions
appeared to be important in determining the impact of a given polymer on crystal growth
for of all three drugs. Among the 22 polymers, specific intermolecular interactions were
only found between PVPVA [(poly(vinylpyrrolidone vinyl acetate)] and celecoxib and
efavirenz. The same group reported again in 2013157 that the effectiveness of these 22
polymers in inhibiting nucleation from aqueous solutions appeared to depend on the
hydrophobicity of the polymer relative to that of the drugs (celecoxib, efavirenz and
ritonavir). Powell et al.170 studied crystal growth in organic glasses (amorphous form) of
three poorly soluble hydrophobic drugs (nifedipine, felodipine and indomethacin) in the
presence of 1% polymers. Interestingly, among the seven polymers tested, the ability to
inhibit crystal growth is not well ordered by the strength of host−polymer hydrogen
bonds, but correlates extremely well with the neat polymer’s glass transition temperature
(Tg), suggesting that the mobility of polymer chains is an important factor in inhibiting
crystal growth in organic glasses. This study was focused on amorphous solids rather
than crystal growth in aqueous solution. However, the outcome of the study indicated that
H-bonds are not dominating stabilization factors and there may be other reasons why
these polymers are so effective at merely 1%.
Therefore, for poorly water-soluble and highly hydrophobic compounds, polymers
capable of forming a hydrophobic interaction would be more important than those with
hydrogen bonding capacities. The MD simulation is capable of providing both VDW and
electrostatic interaction energies to clearly delineate this insight. With the positive results
from this study, it is encouraging to conduct more MD simulation studies in the future

159
using different drug–polymer systems in order to assess the broad impact of VDW
interactions in drug crystallization inhibitions.
Conclusions
We employed MD simulations to study the interaction of an amphiphilic diblock
copolymer (PEG-b-PLA) with tolazamide (001), (010) and (100) crystal surfaces in
water. The very different behaviors of the polymer on each surface can be explained by
different TLZ molecular packing on the surface layer and the differences in polymer–
TLZ interaction energies. The results from the simulations demonstrated the polymer’s
strong interaction with (001), weaker interaction with (010) and minimal to no interaction
with (100), which matched remarkably well with the reported crystal habit alteration by
the preferential interaction of PEG-b-PLA primarily with the (001) and partially with
(010).158,164 The MD simulations suggest that for poorly water-soluble and hydrophobic
drugs, such as tolazamide, the hydrophobic interaction is perhaps more important in
establishing polymer-drug interaction in aqueous solutions. The implication of this
conclusion is that during selection of polymers to inhibit crystallization and to maintain
supersaturation during dissolution of enabling formulations, it is more important to look
for polymers that can engage strong hydrophobic interactions rather than focusing solely
on hydrogen binding capabilities. The consistency between the simulation and
experimental results increased the confidence in further developing MD simulations as a
tool to investigate polymer–drug interactions.
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CHAPTER SIX
GENERAL CONCLUSIONS
This dissertation applied primarily molecular dynamics simulations to investigate
fundamental processes involved in the pharmaceutical aqueous mass transfer phenomena
which are important in drug product research and development. The three separate but
cohesive studies addressed the following questions. First, how does a drug crystal
dissolve into aqueous medium at the molecular level? Secondly, by what mechanism can
one polymorph rapidly convert to another in some cases? Thirdly, how do polymers
interact with a crystal surface to slow down the crystallization or polymorphic
conversion? Interesting results were obtained in each of the three investigations.
In the simulations of acetaminophen crystal Forms I and II dissolving into aqueous
medium, we found that dissolution of the molecules from a crystal surface is not a
random process. The order of the molecules entering the solution is strongly correlated
with the drug–drug and drug–water interaction energies. The molecules at corners and
edges quickly dissolved (corner and edge effect, shown in Figure 40) and those on
different crystal faces dissolved at different rates (crystal face differentiated dissolution
or morphology affected dissolution). Because of the corner and edge effect, there was no
difference in the dissolution rate between the two acetaminophen polymorphs. In
addition, these two nano-sized crystals exhibited much higher dissolution rate than
regular size crystals which could not be accounted for by solubility and surface area
161
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differences. The significance of these findings is two-fold; (1) the crystal morphology is
expected to play a role in the initial dissolution rate, and (2) the existing dissolution
equations based on surface area may not be able to estimate the dissolution rate of
nanocrystals which have greater proportion of their molecules in corners and edges and
countless defects created during milling.

(a)

(b)

Figure 40. Corner and edge effect in drug crystal dissolution. Simulated from dissolution
of ~4.5 nm acetaminophen single crystal in 0.15 M NaCl at 37 °C. Undissolved drug
molecules are shown in line style and dissolved ones are in bulky VDW style. (a) Form I
at 10 ns. (b) Form II at 10 ns.
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In the second study, a series of MD simulations and experimental methods were
utilized to identify which force (thermodynamic or kinetic) is responsible for the rapid
polymorphic transformation of acetaminophen Form II to Form I in solutions. Using a
new solubility method, we reported the first time an accurate measured thermodynamic
solubility of Form II at 37°C. This allowed us to calculate the solubility ratio of Form II
to Form I, which represents the thermodynamic driving force for the conversion. This
value is only 1.27 ± 0.04 and was not high enough to create the supersaturation level to
nucleate Form I. Finally, the molecular dynamics (MD) simulation suggested that large
numbers of acetaminophen molecules were accumulating on the surface of Form II once
in contact with water. This thick disordered molecular layer on Form II surface provides
high local acetaminophen concentration for fast Form I crystallization. This was further
supported by the rapid surface recrystallization of Form I from a Form II crystal in
solution observed by polarized light microscopy and powder X-ray diffraction. The
images from polarized light microscopy (Figure 29) showed no new crystals growing
toward the solution phase, which is a truly surface crystallization phenomenon.
Therefore, we identified a unique polymorphic transition mechanism, termed as SurFPT
(surface facilitated phase transformation), as illustrated shown in Figure 41. This new
mechanism promotes faster polymorphic transformation than the well-known mechanism
of solution-mediated phase transformation (SMPT).
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Figure 41. Schematic illustration of surface facilitated phase transformation (SurFPT).
The metastable form hydrates at once when the water is introduced. The hydrated
molecules quickly accumulate on the surface, approaching a high enough supersaturation
level which leads to crystallization into the more stable solid form.
The third study simulated tolazamide crystal surfaces in the presence of hydrated
PEG-b-PLA, a diblock copolymer for 50 ns in a large water box. In this simulation the
crystals were not allowed to dissolve so that the molecular interaction of the crystal
surface with the polymer was visualized and the interaction energies were calculated. The
results from the simulations demonstrated the polymer’s strong interaction with the (001)
face, weaker interaction with the (010) face and minimal to no interaction with the (100)
face, which matched remarkably well with the reported crystal habit alteration by the
preferential interaction of PEG-b-PLA primarily with the (001) face and partially with the
(010) face. Interestingly, van der Waals interactions were identified as the dominant
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forces, accounting for 77–93% of total interaction energy and enabling strong drug–
polymer interactions on the (001) and (010) faces. These strong van der Waals
interactions require a tight fit between the polymer and the crystal surface, as seen in
Figure 42. These findings suggest that polymers capable of forming strong hydrophobic
interactions are more effective in inhibiting crystallization of poorly water-soluble and
hydrophobic drugs in aqueous media than those with hydrogen bonding capacities. Such
in-depth analysis and understanding facilitate the rational selection of polymers in
designing supersaturation-based enabling formulations.
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Figure 42. PEG-b-PLA polymer–TLZ interaction at the (001) crystal –water interface at
50 ns. The PLA part is located at the left side (color code of the atoms: oxygen is red,
carbon is blue and hydrogen is white). The PEG part is at the right side (color code of the
atoms: oxygen is red, carbon is beige and hydrogen is light pink).

CHAPTER SEVEN
FUTURE RESEARCH
Based on the recently available literature, we believe that the application of MD
simulation in pharmaceutical research and development is still at an early phase. The
results from this dissertation demonstrated that this new technique can significantly
elevate our understanding in drug dissolution, polymorphic transformation and drug–
polymer interactions. Future studies should not only continue in these topics, but also
expand into other topics. Several ideas for future studies are outlined below.
Formulation Excipient Interaction with Drug Molecules
Drug–Polymer Interaction
at the Crystal Surface
It is proposed to evaluate more polymer and drug systems. Structures and
parameters for polymers frequently used in pharmaceutical formulations such as PVP,
PVPVA, HPMC, HPMC-AS, HPC, etc. with or without H-bond capabilities can be
populated as a database. Their interaction with various drug crystals with varied
hydrophobicity can then be studied using our established MD simulation methodology.
The purposes are (1) to evaluate the interaction forces (van der Waals or H-bonding or
ionic) that are important (i.e. the broad impact of van der Waals interaction), and (2) to
determine if the method is viable as a screening tool for rational selection of polymers.
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Drug–Polymer–Surfactant Interaction
and Its Impact on Crystallization
Surfactants are also frequently used in pharmaceutical formulation. Their role in
crystallization of drug molecules in solution will be also very interesting. They can be
studied using the same methodology in the presence or absence of polymers.
Pharmaceutical Nanoparticle Systems
Dissolution of Drug Nanoparticles
We have found that the APAP nanocrystals dissolved very quickly. The fast rate of
dissolution could not be explained by existing knowledge based on the surface area or
solubility. Larger crystals in sizes more close to real nanoparticles (such as 50–100 nm)
can be studied in water when computationally possible. This will help (1) to understand
the dissolution rate with respect to different nano sizes (i.e. at what sizes the dissolution
rate can be described by the equations established for macrosize crystals) and (2) whether
or not the diffusion layer exists. Another interesting study will be to compare the
dissolution behavior of nanocrystals that are water soluble and poorly water-soluble.
The work presented in this dissertation demonstrates that all of these future
studies are, or soon will be, possible.

CHAPTER EIGHT
DISCLOSURE
AbbVie and Loyola University Chicago jointly participated in the study design, research,
data collection, analysis and interpretation of data, writing, reviewing, and approving the
publication. Kenneth W. Olsen is a professor at Loyola University Chicago, and has no
additional conflicts of interest to report. Yi Gao is an employee of AbbVie and may own
AbbVie stock.

169

APPENDIX A
BUILDING CRYSTAL STRUCTURES
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The following is a set of instructions on how to build a crystal surface using Mercury and
VMD.
Open Mercury software and load the drug single crystal structure file. Click
“Packing” to show the unit cell. On the main menu, select Calculate - Packing/Slicing.
Type in the numbers of unit cells to build to the right side of the column under “Pack”.
Maximum of 10 unit cell can be entered. To build more than 10 unit cells, enter 10 on the
right column, then enter minus number (i.e. -7) to the left side column. 17 unit cells will
be built.
Using the building of tolazamide (TLZ) 17x2x8 lattice (010) face as an example,
in “a” direction, enter 10 on the right column, then enter a minus number (i.e. -7) to the
left side column. In “b” direction, enter 2 on the right column. Finally, in the “c”
direction, enter 8 on the right column. It will take a long time for Mercury to build this
large lattice. To check if a correct crystal face is made, under Calculate\Planes\New
Plane, type h=0, k=1 and l=0 (010 phase). It showed (010) is the large surface in 17x2x8
lattice which is correct. Save it as a pdb file.
The lattice file (.pdb) will be viewed as a single chain by VMD rather than as
multiple TLZ molecules. Therefore the following procedure needs to be done to convert
the original pdb to a useful pdb file.


Open the file via Word. Edit/Replace. Replace “UNK” with “TLZ” (the number
spaces between UNK and next column, 1, should remain the same). Save it again
using the original file name of “010_17x2x8.pdb”. Hit OK.
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Delete the rows that do not need to be changed (first few rows until HETATM,
and rows after HETATM). There are hundreds of pages to delete after HETATM.
To speed up, select the starting point to delete, hold down shif/ctrl and hit “End”.
This will select all from the selected rows. Hit “delete”. Save the file as
“010_17x2x8_deleted un-needed rows.pdb”. Hit OK.



Launch Excel program, File/Open “010_17x2x8_deleted un-needed
rows.pdb”/Fixed Width. Click “Next”. Using the mouse to move the arrows that
divide each columns to collapse the vertical lines before and after the column, 1,
and leave only one line right before 1 (not 1.00). Be sure to collapse all vertical
lines.



Click next to open in Excel and save it as “010_17x2x8_deleted un-needed rows
_clapsed.xls”.



Insert 3 columns before the divided line (right before the number 1)



In the 1st new column, type in Space. Copy/paste to the rest of rows.



In the 3rd new column, type %. Copy/paste to the rest of rows.



In the 2nd column, type 1 to the first 42 row (because 42 atoms form one molecule
of TLZ). In the 43st row type in 1+row1, then copy all the way down (Shift/Page
down to move faster). There will be 408 molecules in total. Copy down together
with the 1st and 3rd columns can save time.



Select the 2nd new column, go to Format Cell/Number/Custom, type in 00#, than
hit OK. Now all of the numbers are in the format of 001, 002…., 099…, 408.
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Save it again as “010_17x2x8_deleted un-needed rows_clapsed.xls”. The next
step is to Save it as file type CSV (select comma delimited, *.csv).
010_17x2x8_deleted un-needed rows_clapsed.csv. Hit YES when the next
dialogue shows up.



Open 010_17x2x8_deleted un-needed rows_clapsed.csv in Wordpad.



Replace “,Space,” with two spaces



Replace “,%,1” with no space



After done, there should be 2 spaces before the molecule number, and 6 spaces
after the molecule number.



Save it as .txt file “010_17x2x8_ deleted un-needed rows.txt”. Close the file and
open in Wordpad again.



Open the original pdb file, “010_17x2x8.pdb” also in Wordpad. Select the first a
few rows before HETATM, copy and paste to the beginning of 010_17x2x8_
deleted un-needed rows.txt file. Then select all rows after HETATM
(shift/ctrl/END), copy and paste to the end of above txt file.



Save the final text file as 010_17x2x8.pdb_finalized.pdb. This file can be opened
from VMD shown as single chain for each TLZ molecule.

APPENDIX B
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The following is a set of VMD instructions for making the PDB files needed to measure
the interaction energies, and scripts to calculate interaction energies in the NAMD
program.
Interaction Energy between APAP and Surrounding APAPs
Using APAP# 241 as an example, the first thing to do is to identify the APAP#
surrounding the APAP#241.
1. In VMP, load the psf and pdb files.
2. Run the following in tk console.
set sel [atomselect top "resname APAP and same resid as (resname APAP and within 4 of
resid 241)"]
$sel writepdb 241.pdb
Open the 241.pdb file and 7 APAP# were shown: 242 50 49 33 177 114 178. The
2nd step is to create the following.
set basename apap1_40A
[atomselect top all] set beta 0
[atomselect top "resname APAP and resid 242 50 49 33 177 114 178"] set beta 1
[atomselect top "resid 241"] set beta 2
[atomselect top all] writepdb $basename-interact_241.pdb
The above interact_241.pdb file is used to calculate the interaction of APAP#241
with surrounding APAPs within 4 A.
Interaction Energy between APAP and Surrounding Water
Similarly, use the following to create files for calculation.
set basename apap1_40A_APAPwater
[atomselect top all] set beta 0
[atomselect top "resname TIP3"] set beta 1
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[atomselect top "resname APAP and resname APAP and resid 4"] set beta 2
[atomselect top all] writepdb $basename-interact_4.pdb
Interaction Energy between APAP and NaCl
With Na+:
set basename apap1_40A_APAP_Na
[atomselect top all] set beta 0
[atomselect top "resname SOD"] set beta 1
[atomselect top "resname APAP and resid 61"] set beta 2
[atomselect top all] writepdb $basename-interact_61.pdb
With Cl-:
set basename apap1_40A_APAP_Cl
[atomselect top all] set beta 0
[atomselect top "resname CLA"] set beta 1
[atomselect top "resname APAP and resid 61"] set beta 2
[atomselect top all] writepdb $basename-interact_61.pdb
Interaction Energy between TLZ Crystal Surface
and PEG-b-PLA Diblock Copolymer in Water
The whole polymer was defined as segname O3. For (001) face, the selection of the PLA
and PEG was defined by the following.
PLA part: index 34290 to 34307 or index 34456 to 34510
PEG part: index 34272 to 34289 or index 34308 to 34455
set basename tlz_peg_interact_z
[atomselect top all] set beta 0
[atomselect top "resname TLZ"] set beta 1
[atomselect top "segname O3"] set beta 2
[atomselect top all] writepdb $basename-all.pdb
set basename tlz_peg_interact_z
[atomselect top all] set beta 0
[atomselect top "resname TLZ"] set beta 1
[atomselect top "index 34290 to 34307 or index 34456 to 34510"] set beta 2
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[atomselect top all] writepdb $basename-pla.pdb
The index numbers for (100) face are: PLA part index 16312 to 16366 or index
16146 to 16163. PEG part index 16164 to 16311 or index 16128 to 16145.
The index numbers for (001) face are: PLA part index 23032 to 23086 or index
22866 to 22883. PEG part index 22884 to 23031 or index 22848 to 22865.

MAMD Script to Calculate Interaction Energies
An example script is shown below for the calculation of the PEG chain with the TLZ
crystal (001) face.
# initial config
coordinates tlz_peg_all_z_wb_autopsf.pdb
temperature 0
# output params
outputname
tlz_peg-interact_z_peg
binaryoutput no
# integrator params
timestep
2.0
# force field params
structure tlz_peg_all_z_wb_autopsf.psf
paraTypeCharmm on
parameters par_all27_prot_lipid_apap.inp
parameters Tolazamide.par
parameters Spartan_min1_pdb.par
exclude
scaled1-4
1-4scaling 1.0
switching
on
switchdist 10.0
cutoff
12.0
pairlistdist 13.5
stepspercycle 40
# Atoms in group 1 have a 1 in the B column; group 2 has a 2.
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pairInteraction
on
pairInteractionFile
tlz_peg_interact_z-peg.pdb
pairInteractionCol
B
pairInteractionGroup1 1
pairInteractionGroup2 2
# First frame saved was frame 1000.
set ts 150
coorfile open dcd tlz_peg_all_z_wb_prod_1-50_stride400.dcd
# Read all frames until nonzero is returned.
while { ![coorfile read] } {
# Set firstTimestep so our energy output has the correct TS.
firstTimestep $ts
# Compute energies and forces, but don't try to move the atoms.
run 0
incr ts 150
}
coorfile close

APPENDIX C
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The following are steps to calculate the numbers of molecules dissolved from the crystals
into water.

Claculation of APAP Form I Dissolved with Time
The first step is to identify the 4 APAP resid numbers (167, 218, 234 and 26) located in
the center of the crysal. Then use the VMD to calculate the numbers of molecules
dissolving by the following steps.
•

Load dcd file of APAP1_4x4x4_40A water (1-10 stride 100) and the PSF file.

•

Under Extension/Analysis/RMSD Trajectory tool, enter “resname APAP and

resid 167 218 234 26”. Click “Align” to fix the molecule so that they do not move during
calculation.
•

In Representation, create one with “resname APAP and not within X of (resname

APAP and resid 167 218 234 26)”. X is the radius of the crystal and was found to be 29
for APAP1 in oder to inclue all of the molecules in the crystal at time 0.
•

Run the following sripit.

#get the number of frames
set mol top
set num_steps [molinfo $mol get numframes]
#open file for writing
set fil [open number_apap_disolved.dat w]
#loop over all frames in the trajectory
for {set i 0} {$i < $num_steps} {incr i} {
#select apaps and count
set sel [atomselect top "type OH1 and resname APAP and not within 29 of (resname
APAP and resid 167 218 234 26)"]
$sel frame $i
$sel update
set num_apap [$sel num]
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puts $fil "$i $num_apap"
}
close $fil
Calculation of APAP Form II Dissolved with Time
Similarly, the first step is to identify the 4 molecules located in the center of the Form II
crystal. The script is listed in the following.
#get the number of frames
set mol top
set num_steps [molinfo $mol get numframes]
#open file for writing
set fil [open number_apap_disolved.dat w]
#loop over all frames in the trajectory
for {set i 0} {$i < $num_steps} {incr i} {
#select apaps and count
set sel [atomselect top "type OH1 and resname APAP and not within 27 of (resname
APAP and resid 19 126 162 271)"]
$sel frame $i
$sel update
set num_apap [$sel num]
puts $fil "$i $num_apap"
}
close $fil

APPENDIX D
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Steps to plot the log file for interaction energy profile is described below using
simulation file of APAP1_4x4x4_40 A water box as an exmple.
•

launch VMD.

•

Extensions/Analysis/NAMD plot.

•

Under File, select the log file for plot (e.g corner1.log, a txt file).

•

Click the energy to plot (Electric, VWD and total).

•

Go back to File/Plot selected data.

•

A plot will show up. In the plot, go to File/Export Xmgrace, then save it as

corner1.arg file (click No and ignore the subsequent error message). Each log file will
generate 3 arg files (elect, VDW and total).
•

The saved file can be opened in Excel. From Excel, File/Open .arg file, select

delimited/next/Space/next until finish.
•

Plot elect, VDW and total as 3 groups.

APPENDIX E
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Below are the steps to calculate g(r), pair correlation function as a function of frame
number by the VMD program, using APAP1 as an example.
1. VMD/Load the dcd file of APAP1 at stride 100 and the PSF file.
2. Locate the center molecule (resid 167).
3. Under Extention/Analysis/Trajectory tool, delete “protein”. Enter “resname
APAP and resid 167”. Click “Align” to fix the structure.
4. Under Extention/Analysis/Radial Pair Distribution Function g(r), set up the
following: Selection 1 = resname APAP and resid 167. Selection 2 = resname
APAP. Frame number: from 0 to 0. Step = 1. Delta r = 0.1. Max = 50 (cover the
diameter of the crystal). Click “use PBC”. Click “display g(r)”. Click “Save file”
to save it under a designated folder. Finally, click “computer g(r)”.
5. The file generated can be plotted using Excel.

APPENDIX F
CALCULATION OF NUMBERS OF HYDROGEN BONDS
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Below are steps to calculate the numbers of hydrogen bonds as a function of frame
number by the VMD program, using APAP1 as an example.
1.

In VMD main menu, File/New molecule/Browse/Load the following files.
APAP1_40A_autopsf_ion.psf
APAP1_40A_autopsf_ion_prod_1to10_stride100.dcd

2.

Go to Main menu/Extensions/Analysis/Hbond
a.

Selection: resname APAP

b.

Frames: all

c.

Click to select “Update selection every frame?”

d.

Selection 1 is: both

e.

Donor/acceptor distance: 3.0

f.

Angle cut-off: 20

g.

Calculation detailed information for: unique hbond

h.

Output options
i.

Select “Plot the data to multiplot”

ii.

Directory is automatically selected

iii.

Frame/bond data: hbond.dat

iv.

Details output file: hbond_details.dat

i.

Click “Find hydrogen bonds”

Note that it will take a long time (~15 min) to finish the calculation. Three files will be
saved: gr0.dat, hbonds.dat and hbonds-details.dat. The hbond.dat file can be opened from
the Excel and plotted.
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